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Resumen (Summary) 
El gasto en salud ha aumentado considerablemente durante los últimos 
años en los países occidentales. El envejecimiento de la población es uno de 
los factores que genera ese aumento del gasto sanitario y se prevé un 
incremento constante tanto del envejecimiento poblacional como del gasto en 
salud en el futuro. Por lo tanto, la inversión en estrategias focalizadas en la 
prevención y en el control de las enfermedades crónicas pueden frenar el 
coste sanitario y contribuir a la sostenibilidad de los sistemas sanitarios.  
Los recursos son escasos en comparación con las necesidades, por lo 
que es necesario elegir aquellas alternativas que maximicen el bienestar social. 
Las nuevas tecnologías que se incorporen al sistema sanitario deben 
demostrar una relación positiva entre los resultados obtenidos y los recursos 
utilizados; es decir, deben ser eficientes. Las evaluaciones económicas, 
definidas como el análisis comparativo de acciones alternativas tanto en 
términos de costes como de beneficios, evalúan la eficiencia de las tecnologías 
sanitarias e informan a los gestores sanitarios del valor que generaría la 
financiación de las mismas. 
Los medicamentos representan actualmente la tecnología sanitaria más 
utilizada para controlar y resolver problemas de salud y consumen gran parte 
Resumen 
 12 
 
del presupuesto sanitario. Sin embargo, el uso inefectivo e inseguro de los 
medicamentos genera importantes costes clínicos y económicos prevenibles. 
Diversos procesos fisiológicos y patológicos asociados a la edad aumentan el 
riesgo de sufrir problemas relacionados con los medicamentos en los 
pacientes mayores polimedicados. Por tanto, es necesario realizar un 
seguimiento individualizado de la respuesta de estos pacientes al uso de los 
medicamentos. 
La atención farmacéutica es la provisión responsable de la 
farmacoterapia con el propósito de alcanzar unos resultados concretos que 
mejoren la calidad de vida del paciente. Existen diferentes tipos de servicios 
profesionales farmacéuticos que se realizan en el ámbito de la atención 
farmacéutica y que han demostrado ser efectivos evitando problemas 
relacionados con los medicamentos. Sin embargo, además de los resultados de 
proceso, es necesario evaluar los resultados en salud en relación a los recursos 
necesarios. La evidencia hallada respecto al efecto de los servicios 
profesionales farmacéuticos en resultados en salud y su coste-efectividad varía 
considerablemente, probablemente porque los servicios difieren en el 
objetivo, complejidad y responsabilidad asumida por el farmacéutico. De ahí 
que cada servicio profesional farmacéutico deba ser evaluado individualmente.  
Resumen 
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El seguimiento farmacoterapéutico (SFT) es un servicio profesional 
farmacéutico desarrollado en España y cuyo objetivo consiste en la detección 
de problemas relacionados con los medicamentos, para la prevención y 
resolución de resultados negativos asociados a la medicación. La presente 
tesis doctoral está englobada dentro del Programa conSIGUE, trabajo de 
investigación que se ha llevado a cabo con el objetivo de evaluar el impacto 
clínico, económico y humanístico del servicio de SFT realizado en farmacia 
comunitaria a pacientes mayores polimedicados. El estudio consistió en un 
ensayo controlado aleatorizado por conglomerados, de 6 meses de duración, 
realizado en 178 farmacias de 4 provincias españolas entre 2011 y 2013. Las 
farmacias se aleatorizaron en los grupos de intervención (GI), que realizaron 
SFT, y control (GC), que continuaron con la atención habitual.  
El objetivo principal de la presente tesis doctoral consistió en 
evaluar el impacto económico y los resultados en salud del SFT en 
farmacia comunitaria a pacientes mayores polimedicados.  
Para la consecución de este objetivo, el trabajo se dividió en tres fases:  
En primer lugar se llevó a cabo una revisión sistemática de 
evaluaciones económicas para determinar si los servicios profesionales 
farmacéuticos realizados a pacientes ambulatorios que acuden a la 
Resumen 
Resumen 
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farmacia comunitaria son coste-efectivos en comparación con la 
atención habitual.    
El estudio incluyó las evaluaciones económicas basadas en ensayos 
controlados aleatorizados o ensayos controlados aleatorizados por 
conglomerados realizadas hasta septiembre de 2015. La búsqueda se efectuó 
en MEDLINE, Scopus, Centre for Reviews and Dissemination databases, 
Web of Knowledge y Cochrane Library y se incluyeron un total de 17 
evaluaciones económicas correspondientes a 13 estudios. 
Tras evaluar el riesgo de sesgo de los ensayos y la calidad metodológica 
de las evaluaciones económicas, siete estudios obtuvieron una puntuación 
correspondiente a alta calidad, tres a media y tres a baja calidad. Los servicios 
profesionales farmacéuticos resultaron ser más efectivos y menos costosos 
que la atención habitual en cuatro de los estudios. Siete estudios concluyeron 
que los servicios eran más efectivos y más costosos que la atención habitual. 
En dos de los estudios, los servicios resultaron ser igual de efectivos que la 
atención habitual, con mayor y menor coste en cada caso. A pesar de la 
limitada comparabilidad de los estudios incluidos y la incertidumbre 
relacionada con algunos de los ratios de coste-efectividad incremental, se 
observó una tendencia general hacia el coste-efectividad de los servicios 
profesionales farmacéuticos.  
Resumen 
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Así, en segundo lugar y con el fin de cuantificar el impacto 
económico del SFT realizado en farmacia comunitaria a pacientes 
mayores polimedicados, se llevó a cabo un análisis de costes y un 
análisis de coste-beneficio del Programa conSIGUE. 
El análisis se realizó desde la perspectiva del sistema sanitario con un 
horizonte temporal de 6 meses. Se incluyeron los costes directos médicos 
relativos a la medicación, visitas a urgencias, ingresos hospitalarios 
relacionados con la medicación, tiempo de los farmacéuticos para la 
realización del servicio, tiempo del formador colegial (farmacéutico que asistió 
a la provisión del servicio de SFT y al desarrollo del estudio) y la inversión de 
la farmacia necesaria para la provisión del servicio.  
En el análisis se incluyeron 1403 pacientes (GI: n=688 vs. GC: n=715). 
El análisis de costes mostró que el SFT ahorró 97€ por paciente a lo largo de 
los 6 meses de estudio (€, 2014). Extrapolando los resultados a un año y 
asumiendo que la farmacia recibiera un pago por servicio de 22€ por paciente 
y mes, los ahorros ascenderían a 273€ por paciente y año. En el análisis de 
coste-beneficio, los beneficios en salud se estimaron asignando un valor 
monetario a los años de vida ajustados por calidad obtenidos durante el 
estudio. El ratio de coste-beneficio mostró que por cada euro invertido en 
SFT, se obtuvo un beneficio entre 3,3€ y 6,2€. El análisis de sensibilidad 
Resumen 
Resumen 
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univariante mostró que el SFT ahorraba costes en la mayoría de los escenarios 
considerados y una dominancia del SFT en todos los casos del análisis de 
coste-beneficio. Lo cual permite concluir que el SFT proporciona beneficios 
clínicos a los pacientes y ahorros sustanciales al sistema sanitario, y por tanto 
invertir en este servicio supondría un uso eficiente de los recursos sanitarios.  
En tercer lugar, se cuantificó el impacto del SFT realizado en 
farmacia comunitaria a pacientes mayores polimedicados en el número 
de ingresos relacionados con la medicación y se estimó el efecto en los 
costes hospitalarios. 
Para llevar a cabo este estudio, se realizó un sub-análisis de la muestra 
total de pacientes del Programa conSIGUE, en el que un panel de tres 
expertos en medicina interna cribaron los ingresos hospitalarios ocurridos 
durante los 6 meses de duración del Programa conSIGUE para determinar si 
estaban relacionados con la medicación.  
Entre los 1.403 pacientes del Programa conSIGUE, se produjeron 83 
ingresos hospitalarios. El 50,6% (n=42) estaban relacionados con la 
medicación, alcanzando un nivel de acuerdo sustancial entre los expertos 
medido a través de la Kappa de Fleiss. El número de ingresos relacionados 
con la medicación resultó ser significativamente menor entre los pacientes 
Resumen 
Resumen 
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que recibían SFT, y la probabilidad de ser ingresado fue 3,7 veces mayor en el 
grupo comparación (odds ratio: 3,7; p=0,021). Los costes se estimaron a 
través de los grupos relacionados con el diagnóstico y el coste medio de un 
ingreso relacionado con la medicación fue de 6.672€. El coste medio por 
paciente de los ingresos relacionados con la medicación fue menor para los 
pacientes que recibían SFT (GI: 94€ vs. GC: 301€; p=0,018). Este estudio 
permitió concluir que el SFT realizado por farmacéuticos comunitarios puede 
ser una estrategia efectiva para optimizar el beneficio del uso de 
medicamentos y evitar los ingresos relacionados con la medicación en 
pacientes mayores polimedicados. 
La presente tesis doctoral ha generado evidencia sobre resultados 
económicos y en salud del seguimiento farmacoterapéutico realizado en el 
ámbito de la farmacia comunitaria a pacientes mayores polimedicados. Se ha 
demostrado a través de la revisión sistemática, que los servicios profesionales 
realizados por farmacéuticos comunitarios son en general coste-efectivos, y 
por tanto sería recomendable que se considerase la viabilidad de implantar y 
financiar estos servicios en los sistemas sanitarios. Ha permitido demostrar 
que el SFT es una intervención dominante que mejora la salud de los 
pacientes mientras genera ahorros para el sistema sanitario y que tiene un 
impacto positivo en los ingresos hospitalarios relacionados con la medicación, 
Resumen 
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en tanto que disminuye la probabilidad de ser hospitalizado y los costes 
asociados. El SFT realizado por farmacéuticos comunitarios parece ser una 
estrategia coste-efectiva para responder a las necesidades sanitarias de la 
población mayor, evitar el coste clínico y económico prevenible causado por 
los problemas relacionados con los medicamentos y a largo plazo, promover 
la sostenibilidad de los sistemas sanitarios occidentales. 
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1. Health systems and sustainability 
In recent decades total expenditure on health has increased significantly 
in Western countries, with a percentage of gross domestic product in 
Organisation for Economic Co-operation and Development (OECD) 
countries growing from 7.2% in 2000 to 9% in 20151. Although health 
spending fell across the European Union in 2010 for the first time since 
19752, it is projected to continue rising even assuming cost-containment 
policies3. Population ageing and increased life expectancy is one of the factors 
that will drive healthcare spending in the coming years, along with technology 
innovation to meet new demands, rising prices, and consumer expectations in 
healthcare quality3.  
Increasing life expectancy is leading to an ageing of the European 
population. In countries belonging to the OECD, the population aged 65 or 
over was 8.5% in 1960, 13.8% in 2005 and is projected to grow to 25.2% by 
                                                 
1 OECD Health Statistics 2016 - Frequently Requested Data. Available from: 
http://www.oecd.org/els/health-systems/health-data.htm. [Accesed August 2, 2016]. 
2 OECD Newsroom. Health spending in Europe falls for the first time in decades, 
16/11/12. Availabe from: 
http://www.oecd.org/newsroom/healthspendingineuropefallsforthefirsttimeindecades.htm. 
[Accesed 14 April 2016]. 
3 OECD (2013), “What Future for Health Spending?”, OECD Economics Department 
Policy Notes, No. 19 June 2013. Available from: http://www.oecd.org/economy/health-
spending.pdf. [Accesed 14 April 2016]. 
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20504. In the context of ageing population and the increased prevalence of 
chronic illness, healthcare needs are changing5. Population´s health needs 
must be identified in order to effectively use health resources, and health 
systems must adapt to effectively and efficiently meet these needs. Therefore, 
the investment in strategies focused on prevention and improving the control 
of chronic diseases, might lower future healthcare costs and contribute to the 
sustainability of health systems4.  
Addressing financial sustainability of health systems and responding 
efficiently to healthcare needs of the ageing population are key priority areas 
for European countries. The sustainability of health systems relies on the 
ability of policy makers adequately to manage and finance healthcare 
resources to meet population needs6.  
A high percentage of these healthcare needs can be met by primary care 
services6. Since costs in primary care are lower than in secondary, care should 
                                                 
4 Rechel B, Doyle Y, Grundy E, McKee M. How can health systems respond to population 
ageing? WHO Regional Office for Europe, on behalf of the European Observatory on 
Health Systems and Policies. Copenhagen, 2009. Available from: 
http://www.euro.who.int/__data/assets/pdf_file/0004/64966/E92560.pdf. [Accessed July 
28, 2016]. 
5 Nolte E, McKee M. Caring for people with chronic conditions : a health system perspective. 
Maidenhead: Open University Press; 2008. 
6 Thomson S, Foubister T, Figueras J, Kutzin J, Permanand G, Bryndová L. Addressing 
financial sustainability in health systems. WHO Regional Office for Europe on behalf of the 
European Observatory on Health Systems and Policies. Copenhagen, 2009. Available from: 
http://www.euro.who.int/__data/assets/pdf_file/0005/64949/E93058.pdf?ua=1. [Accessed 
July 27, 2016]. 
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be delivered in the primary level when possible. The breadth and scope of 
services that can be provided in primary care should be expanded, and the 
better coordination across different healthcare settings is crucial7. 
Policies intended to ensure the sustainability of health systems can be 
directed to one of the following three key points: to define the amount to be 
spent on healthcare, to decide the level of coverage to be provided by the 
health system and how to increase the value from existing health system 
resources. The last approach is based on the optimization of the outcomes 
gained by healthcare and the efficiency of the new financed technologies 
while outweighing the opportunity cost6. 
                                                 
7 Figueras J, McKee M, Lessof S, Duran A, Menabde N. Health systems, health and wealth: 
assessing the case for investing in health systems. WHO Regional Office for Europe on 
behalf of the European Observatory on Health Systems and Policies. Copenhagen, 2008. 
Available from: http://www.euro.who.int/__data/assets/pdf_file/0009/83997/E93699.pdf. 
[Accessed July 28, 2016]. 
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2. Economic evaluations 
There is no perfect competition in medical care markets and the 
intervention of non-market institutions is needed to enhance the efficiency of 
the systems8. The funding of health systems in OECD countries is mainly 
public, thus governments and health authorities make decisions on funding 
health technologies based on equity, accessibility and efficiency of health 
technologies9. 
Resources are scarce relative to the needs, and decisions must be made 
to choose the alternative which maximizes social welfare10. Efficiency is the 
relationship between the outcomes achieved and the resources used, and 
measures whether healthcare resources are getting the best value for money11. 
Lower costs do not imply more efficiency, neither higher costs better 
outcome. Therefore, any new technology incorporated into the health system 
must demonstrate a positive relationship between resources required and 
                                                 
8 Arrow KJ. Uncertainty and the welfare economics of medical care. 1963. Bull World Health 
Organ. 2004;82(2):141-9. 
9 Pinto JL, Sánchez FI. [Methods for the economic evaluation of new technologies]. Ministry 
of Health and Consumer Affairs: Madrid; 2003. Available from: 
http://www.msssi.gob.es/estadEstudios/estadisticas/docs/metodos_evaluacion.pdf. 
[Accessed April 14, 2016]. 
10 Liss PE. Allocation of scarce resources in health care: values and concepts. Texto 
Contexto. Enferm. 2006;15:125-34. 
11 Palmer S, Torgerson DJ. Economic notes: definitions of efficiency. BMJ. 
1999;318(7191):1136. 
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outcomes achieved. Distributing available resources using the efficiency 
criterion, allows health outcomes to be optimised and to minimize the 
opportunity cost12. 
 The economic evaluation (EE) is one of the methodologies that have 
been proposed to select those efficient medical technologies9. EE is defined 
as “the comparative analysis of alternative courses of action in terms of both 
their costs and consequences”13. It compares all the necessary resources for 
the provision of a health technology and the consequences with the best or 
most widely used alternative. This facilitates the process of decision making 
for a rational choice among alternative technologies. EE are needed to inform 
decision makers on the value of financing new technologies. 
                                                 
12 Culyer AJ. Encyclopedia of Health Economics. 1st edition. UK: Oxford. Elsevier; 2014. 
13 Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the 
Economic Evaluation of Health Care Programmes. 3rd edition. Oxford: Oxford University 
Press; 2005. 
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3. Medicines and drug related problems 
Medicines are the most widely used technology to manage and resolve 
health problems. They improve patients´ clinical outcomes and quality of life, 
as well as extend the overall life expectancy. An important percentage of 
healthcare budget is spent in medicines. For instance, prescription drugs 
consume 10% of the healthcare spending in the U.S.14. However, the clinical 
and economic burden associated with the ineffective and unsafe use of 
medicines is widely documented, as well as the preventability of a substantial 
proportion of drug related problems (DRPs). 
A high percentage of DRPs result in emergency department (ED) visits 
or/and hospital admissions. Systematic reviews of studies undertaken in the 
hospital setting found a median prevalence of 5.3% adverse drug reactions15 
and 10% of adverse events in hospital admissions, with 50% of them being 
preventable16. A series of three studies undertaken in Spanish hospital 
emergency departments found that between 24.4% and 35.7% of the ED 
                                                 
14 Baker D, Fugh-Berman A. Do New Drugs Increase Life Expectancy? A Critique of a 
Manhattan Institute Paper. J Gen Intern Med. 2009;24(5):678-82. 
15 Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug 
reactions: a systematic review of prospective observational studies. Ann Pharmacother. 
2008;42(7):1017-25. 
16 Vries EN, Ramrattan MA, Smorenburg SM, Gouma DJ, Boermeester MA. The incidence 
and nature of in-hospital adverse events: a systematic review. Qual Saf Health Care. 
2008;17(3):216–23. 
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visits were caused by negative clinical outcomes related to medicines 
(NCOMs), of which from 73% to 83.9% were preventable17,18,19. 
An ageing population and the use of polypharmacy are well 
documented risk factors for DRPs and medication-related hospital 
admissions18,20. The study carried out by Chan et al. with aged patients using 
eight or more medications found that 87% of the analysed patients had at 
least one DRP21. When analysing patients with a mean age of 81 and using 15 
medicines, the prevalence of DRPs per patient was 8.922. The main reasons 
for the higher risk of DRPs in the elderly are the changes in pharmacokinetics 
and pharmacodynamics parameters due to the physiological and pathological 
changes related to the age and the chronic use of medicines, the higher 
prevalence of co-morbidity of chronic illness, and the complex therapeutic 
management due to the polypharmacy for chronic diseases. Additionally, 
                                                 
17 Baena MI, Fajardo PC, Pintor-Marmol A, Faus MJ, Marin R, Zarzuelo A et al. Negative 
clinical outcomes of medication resulting in emergency department visits. Eur J Clin 
Pharmacol. 2014;70(1):79-87. 
18 Baena MI, Faus MJ, Fajardo PC, Luque FM, Sierra F, Martinez-Olmos J, et al. Medicine-
related problems resulting in emergency department visits. Eur J Clin Pharmacol 2006; 62(5): 
387–93. 
19 García V, Marquina I, Olabarri A, Miranda G, Rubiera G, Baena MI. [Negative results 
associated with medication in the emergency department of a hospital]. Farm Hosp 
2008;32(3):157-62. 
20 Rogers S, Wilson D, Wan S, Griffin M, Rai G, Farrell J. Medication-related admissions in 
older people: a cross-sectional, observational study. Drugs Aging. 2009;26(11):951-61. 
21 Chan DC, Chen JH, Kuo HK, We CJ, Lu IS, Chiu LS, et al. Drug-related problems (DRPs) 
identified from geriatric medication safety review clinics. Arch Gerontol Geriatr. 
2012;54(1):168-74. 
22 Farrell B, Szeto W, Shamji S. Drug-related problems in the frail elderly. Can Fam Physician 
2011;57(2):168-9. 
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geriatric patients have a greater incidence of cognitive and functional 
disabilities, which increases the risk of using medicines incorrectly, affecting 
for instance the adherence23.  
DRPs use social and health resources and generate costs to the 
healthcare system. In the U.S., the cost of treating drug-related morbi-
mortality in ambulatory care was estimated to be $177.4 billion in 2000 year24 
and avoidable healthcare costs generated by DRPs amounted to $200 billion 
in 201225. In Spain, the cost in ED visits caused by preventable NCOMs was 
estimated to be €14.5 million during the 2003 year19. In the Netherlands 
potentially preventable medication-related hospital admissions cost more than 
€94 million in 200626. The annual cost of outpatients’ drug-related morbidity 
was estimated to be €6,600 million in 2012 for the Swedish healthcare system, 
with 45% of this morbidity being preventable27. Therefore, an individualized 
                                                 
23 Malet-Larrea A, Calvo B. [Impact of the Medication Review with Follow-up in the 
polymedicated elderly. The conSIGUE Program in Gipuzkoa]. Masters dissertation. Vitoria: 
University of the Basque Country; 2013. 
24 Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness 
model. J Am Pharm Assoc (Wash). 2001;41(2):192-9. 
25 Aitken, M. Valkova, S. Avoidable costs in U.S. healthcare: the $200 billion opportunity 
from using medicines more responsibly. USA: IMS Institute for Healthcare Informatics; 
2013. Availabe from: 
http://www.imshealth.com/files/web/IMSH%20Institute/Reports/Avoidable_Costs_in%2
0_US_Healthcare/IHII_AvoidableCosts_2013.pdf. [Accessed May 10, 2016]. 
26 Leendertse AJ, Bemt PM, Poolman JB, Stoker LJ, Egberts AC, Postma MJ. Preventable 
hospital admissions related to medication (HARM): cost analysis of the HARM study. Value 
Health. 2011;14(1):34-40. 
27 Gyllensten H, Hakkarainen KM, Jonsson AK, Andersson Sundell K, Hagg S, Rehnberg C 
et al. Modelling drug-related morbidity in Sweden using an expert panel of pharmacists'. Int J 
Clin Pharm. 2012;34(4):538-46. 
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follow-up of patients´ response to medicines is required, especially in aged 
patients using polypharmacy, in order to avoid the preventable clinical and 
economic burden caused by DRPs. 
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4. Professional pharmacy services 
 “Pharmaceutical care” concept promoted by Hepler & Strand in 1990 
was defined as “the responsible provision of drug therapy for the purpose of 
achieving definite outcomes that improve a patient's quality of life”28, 
highlighting the transition of a product-oriented to patient-oriented pharmacy 
practice. However the adoption and implementation of this professional role 
has been patchy between and within countries29.  
The concept of pharmaceutical care has been crystallised into a more 
acceptable, understandable and practical construct i.e. a professional 
pharmacy services (PPSs). Several definitions and concepts have been 
developed for the pharmaceutical care30,31 and PPSs (for instance, clinical 
pharmacy services32 or cognitive pharmaceutical services33). All these 
                                                 
28 Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J 
Hosp Pharm. 1990;47(3):533-43. 
29 van Mil JWF, Schulz M. A Review of Pharmaceutical Care in Community Pharmacy in 
Europe. Harv Health Pol Rev. 2006;7(1):155-68. 
30 Allemann SS, van Mil JW, Botermann L, Berger K, Griese N, Hersberger KE. 
Pharmaceutical care: the PCNE definition 2013. Int J Clin Pharm. 2014; 36(3):544-55. 
31 Pharmaceutical Care Forum. Expert panel. Consensus document. Madrid: Spanish General 
Council of Official Colleges of Pharmacists; 2010 (ISBN: 9788469112434). 
32 Perez A, Doloresco F, Hoffman JM, Meek PD, Touchette DR, Vermeulen LC, et al. 
ACCP: economic evaluations of clinical pharmacy services: 2001-2005. Pharmacotherapy. 
2009;29(1):128. 
33 Benrimoj SI, Feletto E, Gastelurrutia MA, Martinez-Martinez F, Faus MJ. A holistic and 
integrated approach to implementing cognitive pharmaceutical services. Ars Pharm 2010;51: 
69-87. 
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definitions, although with minor variations, address the same underlying 
philosophy. 
PPSs are provided in community, hospital and long-term care settings. 
They are mainly aimed at optimising medication therapy and managing 
chronic diseases, although the prevention and resolution of acute conditions 
is also considered. Some services are focused in one health problem whereas 
other services analyse patients from a holistic approach. The “Hierarchical 
model of cognitive pharmaceutical services” classifies PPSs in ten different 
levels of pharmacists´ interventions, according to their complexity of clinical 
decision making (Table 1). Level 1 is the simplest intervention, provision of 
information about medicines, and level 10 is the most complex, medication 
prescribing33. Medication review with follow-up (MRF) is a service included in 
the level 7, focused on both medication use process and health outcomes, and 
requires a commitment to follow-up.  
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Table 1: Hierarchical model of professional pharmacy services33 
1. Medicines information 
2. Compliance, adherence and/or concordance 
3. Disease screening 
4. Disease prevention 
5. Clinical intervention or identification and resolving drug related 
problems 
6. Medication use reviews 
7. Medication management/medication therapy management 
7.a Home medication reviews 
7.b Residential care home medication reviews 
7.c Medication reviews with continuance follow-up 
8. Disease state management for chronic conditions 
9. Participation in therapeutic decisions with medical practitioners 
9.a In clinical setting 
9.b In the pharmacy 
10. Prescribing 
10.a Supplementary 
10.b Independent 
 
4.1 Clinical and economic impact of professional 
pharmacy services 
There is a growing evidence of the positive effect of several PPSs on 
improving pharmacotherapy and reducing DRPs such as the number of 
medicines used by patient and improving the appropriateness of the 
medication in elderly patients34,35. However, their effectiveness on reducing 
hospital admissions in aged patients has not been clearly established34. 
                                                 
34 Saez-Benito L, Fernandez-Llimos F, Feletto E, Gastelurrutia MA, Martinez-Martinez F, 
Benrimoj SI. Evidence of the clinical effectiveness of cognitive pharmaceutical services for 
aged patients. Age Ageing. 2013;42(4):442-9. 
35 Spinewine A, Fialova D, Byrne S. The role of the pharmacist in optimizing 
pharmacotherapy in older people. Drugs aging. 2012;29(6):495-510. 
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Different and inconclusive findings have been found in several systematic 
reviews addressing this topic36,37. 
Diverse findings have been found not only in health outcomes but also 
in the cost-effectiveness of PPSs. Some studies concluded that PPSs were 
more effective and less costly than usual care (UC)38 while others found 
higher costs for PPSs39,40. Several systematic reviews conclude that PPSs 
provided in different settings generally provide positive economic benefits, 
although the variability in both health outcomes and the subsequent cost-
effectiveness analysis (CEA) is high32,41,42,43. 
                                                 
36 Holland R, Desborough J, Goodyer L, Hall S, Wright D, Loke YK. Does pharmacist-led 
medication review help to reduce hospital admissions and deaths in older people? A 
systematic review and meta-analysis. Br J Clin Pharmacol. 2008;65(3):303–16. 
37 Thomas R, Huntley AL, Mann M, Huws D, Elwyn G, Paranjothy S, et al. Pharmacist-led 
interventions to reduce unplanned admissions for older people: a systematic review and meta-
analysis of randomised controlled trials. Age ageing. 2014;43(2):174-87. 
38 Elliott RA, Barber N, Clifford S, Horne R, Hartley E. The cost effectiveness of a 
telephone-based pharmacy advisory service to improve adherence to newly prescribed 
medicines. Pharm World Sci. 2008;30(1):17-23. 
39 RESPECT Trial Team. Cost-effectiveness of shared pharmaceutical care for older patients: 
RESPECT trial findings. Br J Gen Pract. 2010;60(570):e20-7. 
40 Gordois A, Armour C, Brillant M, Bosnic-Anticevich S, Burton D, Emmerton L, et al. 
Cost-Effectiveness Analysis of a Pharmacy Asthma Care Program in Australia. Dis-Manage-
Health-Outcomes. 2007;15:387-96. 
41 Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist 
interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 
2014;36(6):1101-14. 
42 Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL, et al. 
Evidence of the economic benefit of clinical pharmacy services: 1996-2000. 
Pharmacotherapy. 2003;23(1):113-32. 
43 Schumock GT, Meek PD, Ploetz PA, Vermeulen LC. Economic evaluations of clinical 
pharmacy services:1988-1995. Pharmacotherapy. 1996;16(6):1188-208. 
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Settings in which PPSs are provided, variability in assessing complex 
interventions44 or strengths and flaws of different studies may explain 
different findings. However, the main reason could be that every service 
differs widely in its aims, methodology, complexity, collaboration with other 
healthcare providers and level of responsibility assumed by the pharmacist33 
and therefore logically the same outcomes cannot be assumed for different 
types of PPSs.  
4.2  Medication review with follow-up and conSIGUE 
Program 
MRF is a service developed in Spain and defined according to Spanish 
national guidelines as “the professional pharmacy service aimed at identifying 
drug related problems in order to prevent and resolve negative clinical 
outcomes related to medicines. It requires a commitment, and it must be 
delivered in a continuous, systematic and registered way, in collaboration with 
the patient and other health professionals, with the aim of achieving definite 
outcomes that will improve patient´s quality of life”31. 
                                                 
44 Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M, et al. Developing and 
evaluating complex interventions: the new Medical Research Council guidance. BMJ. 
2008;337:a1655. 
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MRF starts with the pharmacist´s interview undertaken in a private area 
of the pharmacy. The pharmacist collects relevant information about patient’s 
health problems, medicines used, clinical and biological parameters (gathered 
through medical records provided by the patient or measured in the 
pharmacy), medication use, lifestyle habits and concerns about diseases and 
medications. The pharmacist records this information in a tool called 
“situational analysis”. After undertaking the study phase for all the health 
problems and medicines, a comprehensive medication review is undertaken. 
The pharmacist identifies drug related problems and negative clinical 
outcomes related to medicines. Subsequently an action plan is agreed with the 
patient and the physician if required. Pharmacist´s interventions follow the 
action plan. Monthly patient visits to the pharmacy are used for patient´s 
monitoring and performing new interventions45 (see Figure 1). 
 
                                                 
45 Malet-Larrea A, Goyenechea E, Garcia-Cardenas V, Calvo B, Arteche JM, Aranegui P, et 
al. The impact of a medication review with follow-up service on hospital admissions in aged 
polypharmacy patients. Br J Clin Pharmacol. 2016; 82(3):831-8. 
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Figure 1: Process of the medication review with follow-up 
 
The aim of the conSIGUE Program46, carried out between 2009 and 
2013, was to assess the clinical, economic and humanistic impact of the MRF 
provided to aged patients with polypharmacy in community pharmacy. A 
cluster randomized controlled trial (c-RCT) was carried out in 178 community 
                                                 
46 Martínez-Martínez F, Gastelurrutia MA, Benrimoj SI, García-Cárdenas V, Saez-Benito L, 
Varas R. [conSIGUE: clinical, economic and humanistic impact of the Medication Review 
with Follow-up service in aged polypharmacy patients in Spanish community pharmacy]. 
Madrid: Spanish General Council of Official Colleges of Pharmacists; 2014. ISBN: 978-84-
87276-83-5. 
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pharmacies in four Spanish provinces (Guipúzcoa, Granada, Las Palmas and 
Tenerife) between November 2011 and July 2013, with 6 months fieldwork in 
each province. All the community pharmacies located in the four provinces 
received an invitation to participate in the study from the provincial official 
associations of pharmacists, with all the respondents enrolled. Each pharmacy 
was required to recruit up to 10 patients with the following criteria: aged 
patients (65 years or older), using polypharmacy (five or more medications for 
at least 6 months) and with the ability to complete the EuroQol 5D (EQ-5D) 
questionnaire. Pharmacies were the cluster unit of randomization in order to 
minimize contamination bias, and they were randomly allocated into either 
the intervention group (IG) or comparison group (CG). Pharmacists in the 
IG provided MRF whereas pharmacists in the CG provided the UC in 
Spanish community pharmacies, which consists of dispensing medicines 
prescribed by physicians and minor ailments advice47.  
A specifically trained pharmacist called a practice change facilitator48 
assisted pharmacists of the IG in the provision of the MRF, identifying 
barriers and facilitators specific to each pharmacy and providing solutions. 
Additionally, the practice change facilitator ensured fidelity using process 
                                                 
47 Gastelurrutia MA, Faus MJ, Fernandez-Llimos F. Providing patient care in community 
pharmacies in Spain. Ann Pharmacother. 2005;39(12):2105-10. 
48 Harvey G, Loftus-Hills A, Rycroft-Malone J, Titchen A, Kitson A, McCormack B, et al. 
Getting evidence into practice: the role and function of facilitation. J Adv Nurs. 
2002;37(6):577-88. 
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indicators to the intervention and supported pharmacists of both study 
groups on doubts about documentation forms. Pharmacists in the IG 
received a 3 day training course covering the following topics: clinical 
management of aged patients, the MRF method, communication with 
patients and doctors, study protocol and documentation forms. Study 
variables, including variables used in the economic evaluation of the MRF 
presented in this thesis, were collected on a monthly basis during the c-RCT. 
The study was approved by the Clinical Research Ethics Committee of the 
Hospital Virgen de las Nieves of Granada (Spain) in November 2009. All 
patients were provided with an information sheet prior to the beginning of 
the study and informed consent was obtained. Detailed methods and 
preliminary results of the study can be accessed in Spanish in the report 
published by the Spanish General Council of Official Colleges of 
Pharmacists46. 
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Health expenditure in western countries is steadily increasing and it 
could lead to unsustainable health systems in the coming years. Developing 
and implementing efficient technologies to meet ageing population´s 
demands should be a key health investment area. 
The incorrect use of medicines causes significant and preventable 
clinical and economic burden. Ensuring the effective and safe use of 
medication would improve patients´ health and quality of life, as well as avoid 
unnecessary costs to the health system.  
Professional pharmacy services have shown promising results and could 
be one of the strategies to ensure the correct use of medicines, meet aged 
population´s health needs and promote the sustainability of health systems.  
The main aim of this thesis was to assess the economic impact and 
health outcomes of the community pharmacist-led medication review with 
follow-up to aged patients using polypharmacy. The specific goals were the 
following: 
1. To systematically and critically analyse the existing evidence to 
determine whether professional pharmacy services provided to 
ambulatory patients attending community pharmacies are cost-
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effective compared with usual care. Furthermore, the methodological 
quality of individual studies was assessed and cost-effectiveness data 
were synthesized to facilitate the consideration of implementing 
professional pharmacy services in health systems (addressed through 
Chapter 1). 
 
2. To assess the economic impact of the medication review with follow-
up provided in community pharmacy to aged patients using 
polypharmacy compared with usual care, through a cost-analysis and a 
cost-benefit analysis based on the conSIGUE cluster randomized trial 
(addressed through Chapter 2). 
 
3. To analyse the effect of community pharmacy-led medication review 
with follow-up provided to aged polypharmacy patients on the 
number of medication-related hospital admissions, using an expert 
panel to ascertain whether the hospital admissions of the conSIGUE 
Program were medication related. Additionally, the impact of the 
medication review with follow-up on hospital costs was estimated 
(addressed through Chapter 3). 
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Objetivos 
El aumento continuo del gasto sanitario en los países occidentales 
podría dar lugar en los próximos años a sistemas sanitarios insostenibles. El 
desarrollo e implantación de tecnologías eficientes que cubran las necesidades 
de la población mayor debería ser un área prioritaria de inversión sanitaria. 
El uso incorrecto de los medicamentos causa daños clínicos y 
económicos significativos y prevenibles. Garantizar el uso efectivo y seguro 
de la medicación podría mejorar la calidad de vida de los pacientes, así como 
evitar costes innecesarios al sistema sanitario. 
Los servicios profesionales farmacéuticos han mostrado resultados 
prometedores y podrían ser una de las estrategias para asegurar el uso 
correcto de los medicamentos, cubrir las necesidades sanitarias de los 
pacientes mayores y promover la sostenibilidad de los sistemas sanitarios.  
El objetivo principal de la presente tesis doctoral consistió en evaluar el 
impacto económico y los resultados en salud del seguimiento 
farmacoterapéutico realizado en farmacia comunitaria a pacientes mayores 
polimedicados.  
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Los objetivos específicos que se propuso alcanzar este trabajo fueron 
los siguientes: 
1. Analizar sistemática y críticamente la evidencia existente para 
determinar si los servicios profesionales farmacéuticos realizados a 
pacientes ambulatorios que acuden a la farmacia comunitaria son 
coste-efectivos en comparación con la atención habitual. Además se 
evaluó la calidad metodológica de los estudios individuales y se 
sintetizaron los resultados de coste-efectividad, para facilitar la 
consideración de implantar servicios profesionales farmacéuticos en 
los sistemas sanitarios (abordado en el Capítulo 1). 
 
2. Evaluar el impacto económico del seguimiento farmacoterapéutico 
realizado en farmacia comunitaria a pacientes mayores polimedicados 
en comparación con la atención habitual, mediante un análisis de 
costes y un análisis de coste-beneficio basados en el ensayo clínico 
aleatorizado por conglomerados del Programa conSIGUE (abordado 
en el Capítulo 2). 
 
3. Analizar el efecto del seguimiento farmacoterapéutico realizado en 
farmacia comunitaria a pacientes mayores polimedicados sobre el 
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número de ingresos relacionados con la medicación, utilizando un 
panel de expertos para determinar la relación de los ingresos 
hospitalarios del Programa conSIGUE con la medicación. Asimismo 
se estimó el efecto del seguimiento farmacoterapéutico en los costes 
hospitalarios (abordado en el Capítulo 3).  
Objectives 
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1.1 Introduction 
Clinical and economic burden of DRPs has been widely documented. 
DRPs including medication nonadherence, inappropriate polypharmacy in 
older adults and medication errors generated $200 billion of avoidable 
healthcare costs in the U.S. in 2012 year49. The annual cost of outpatients’ 
drug-related morbidity was estimated to be €6,600 million for the Swedish 
health system for the same year, with 45% of this morbidity being 
preventable27. A systematic review of observational studies concluded that the 
median prevalence of adverse drug reactions in hospital admissions was 
5.3%15. The prevalence of NCOMs in nine Spanish hospital emergency 
department visits was 35.7%, of which 81% could have been prevented17.  
PPSs are “any activity in which the pharmacists would use their 
professional knowledge and abilities to improve pharmacotherapy and disease 
management by means of interacting with the patient or with other health 
professional”50. A systematic review showed that PPSs are an effective 
strategy to prevent and resolve drug related problems, such as medication 
                                                 
49 Aitken, M. Valkova, S. Avoidable costs in U.S. healthcare: the $200 billion opportunity 
from using medicines more responsibly. USA: IMS Institute for Healthcare Informatics; 
2013. Availabe from: 
http://www.imshealth.com/files/web/IMSH%20Institute/Reports/Avoidable_Costs_in%2
0_US_Healthcare/IHII_AvoidableCosts_2013.pdf. [Accessed May 10, 2016]. 
50 Cipolle J, Strand LM, Morley PC. A Reimbursement System for Pharmaceutical Care: 
Pharmaceutical Care Practice. New York: McGraw-Hill, 1998. 
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non-adherence or inappropriate medications34. PPSs have been shown to 
decrease medication-related hospital admission rates in aged polypharmacy 
patients45, as well as to improve clinical outcomes and reduce hospitalisation 
rates, general practice and ED visits in a systematic review including studies 
conducted in low and middle-income countries51. The economic implications 
of clinical pharmacy services have been reported32,42,43,52. While the cost-
effectiveness of clinical pharmacist interventions on hospital inpatients has 
already been specifically analysed41, there are no systematic reviews analysing 
their cost-effectiveness in the community pharmacy setting.  
Therefore, the objective of this systematic review was to determine 
whether PPSs provided to ambulatory patients attending community 
pharmacies are a cost-effective strategy to improve patients´ clinical and 
humanistic outcomes compared to UC. We provide data in a visual and 
simple method for decision makers to assess whether they should evaluate the 
feasibility of implementing PPSs in their specific health systems. 
                                                 
51 Pande S, Hiller JE, Nkansah N, Bero L. The effect of pharmacist-provided non-dispensing 
services on patient outcomes, health service utilisation and costs in low- and middle-income 
countries. Cochrane Database Syst Rev. 2013;2:CD010398. 
52 Touchette DR, Doloresco F, Suda KJ, Perez A, Turner S, Jalundhwala Y, et al. Economic 
evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy. 2014;34(8):771-93. 
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1.2 Methods 
The Cochrane Handbook for Systematic Reviews of Interventions53 
and the NHS Economic Evaluation Database Handbook54 methodology were 
followed. The reporting of this systematic review followed the guidelines 
provided by PRISMA statement55,56. 
1.2.1 Selection criteria 
A systematic review of full EE based on randomised or cluster 
randomised controlled trials (RCT/c-RCT) of professional pharmaceutical 
services provided to ambulatory patients attending community pharmacy was 
conducted.  
                                                 
53 Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. 
Available from www.cochrane-handbook.org. [Accesed 8 Sept 2015]. 
54 NHS Centre for Reviews and Dissemination. NHS Economic Evaluation Database 
Handbook. UK: University of York; 2007. Available from: 
http://www.york.ac.uk/inst//crd/pdf/nhseed-handbook2007.pdf. [Accessed September 20, 
2015]. 
55 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The 
PRISMA statement for reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. 
56 Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. BMJ. 
2009;339:b2535. 
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Full EE were included, as they allow assessing the efficiency of health 
technologies. Drummond´s definition for full EE was adopted (“studies 
reporting both costs and consequences of at least two alternatives”)13. These 
full EEs were subcategorized as cost-effectiveness, cost-minimization, cost-
utility, cost-consequence or cost-benefit analysis, depending on the units used 
to measure outcomes. PPSs were defined using Cipolle’s definition50 and 
categorized using the “Hierarchical model of cognitive pharmaceutical 
services”, which comprises 10 different levels of pharmacists´ interventions, 
according to their complexity of clinical decision making33. For the purpose of 
this study, we combined level 6 (medication use review) and level 7 
(medication therapy management) leading to a category of “medication 
therapy management with/without follow-up”.  
The exclusion criteria were: (i) studies assessing interventions that were 
not considered PPSs based on Cipolle’s definition50 and on the hierarchical 
model33; (ii) studies in which the service was not exclusively provided by a 
pharmacist to ambulatory patients recruited in the community pharmacy; (iii) 
not full EE based on Drummond’s definition13; (iv) studies in which the main 
cost and effectiveness data were not gathered from a single RCT/c-RCT 
study, (v) studies not including the main types of costs from the perspective 
of the society, government, health system or third party; (vi) studies not 
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comparing a PPS with the UC; (vii) letters, study protocols, notes, 
commentaries, guidelines, conference abstracts, pilot studies, literature 
reviews, meta-analysis and papers without abstract; and (viii) papers not 
written in languages with Latin alphabet. 
1.2.2 Article retrieval and screening 
The databases searched from inception to 2015 were MEDLINE, Web 
of Knowledge, Centre for Reviews and Dissemination Database, the 
Cochrane Library and Scopus.  
Queries were built by examining the Mesh terms of potentially relevant 
studies and combining them with keywords. Publication date filter was not 
used. Previously published filters for EE and gathered by the InterTASC 
Information Specialists' Sub-Group Search Filter Resource were consulted to 
ensure the inclusion of all the relevant terms57. 
The search strategy used in MEDLINE was: (“Economic 
evaluation”[TIAB] OR “cost”[TIAB] OR “costs and cost analysis”[MH] OR 
“economic impact”[TIAB] OR “pharmacoeconomic”[TIAB] OR “economic 
                                                 
57 The InterTASC Information Specialists' Sub-Group Search Filter Resource. Filters to find 
Economic Evaluations [internet]. UK. Available from: 
https://sites.google.com/a/york.ac.uk/issg-search-filters-resource/filters-to-find-i. [Accessed 
Sept 20, 2015]. 
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outcomes”[TIAB] OR “cost-effectiveness”[TW] OR “cost-utility”[TW] OR 
“cost-benefit”[TW] OR “cost-minimization”[TW] OR “quality adjusted life 
years”[MH] OR “quality of life”[MH]) AND (“community pharmacy 
services”[MH] OR "medication review"[TIAB] OR (pharmacist* [TW] AND 
("drug utilization review"[MH] OR "cognitive services"[TIAB])) OR 
“pharmaceutical services”[MH] OR “pharmaceutical care”[TW] OR 
“cognitive services”[TW] OR intervention*[TIAB] OR “professional 
role”[MH]) AND (“pharmacists”[MH] OR “pharmacies”[MH] OR 
pharmaci*[TW] OR “pharmacy”[TIAB]) NOT (review[PT] OR 
comment[PT] OR “newspaper article”) AND HASABSTRACT. The search 
strategy was adapted for other databases using the appropriate syntax and 
terms (all search strategies are available from authors). Search strategy was 
tested by screening selected citations for relevance. The references of the 
retrieved papers were reviewed for additional relevant studies and two experts 
in PPSs checked their libraries (CB & VGC).  
The literature selection process was undertaken and discussed by two 
researchers on PPSs (AML and LSB). This process was over inclusive. 
Discrepancies between reviewers were resolved with the opinion of a third 
researcher (EG). 
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1.2.3 Data extraction, quality assessment and analyses 
A tailored data extraction form based on Cochrane53 and NHS 
handbook54 data extraction forms was developed and piloted for data retrieval 
and analysis. It included information about the study characteristics (citation, 
objective, study design, randomization, follow-up and sample size), the PPS 
(type of service according to the hierarchical model, description of the 
intervention and the comparator, remuneration and training of pharmacists), 
clinical and humanistic outcomes (differences between groups, tools used to 
measure the outcomes), costs (currency and year, direct medical costs, direct 
non-medical costs, indirect costs), economic evaluation (type of economic 
evaluation, perspective, time horizon, discount rate, incremental analysis, 
sensitivity analysis) and miscellaneous (conclusions, limitations, funding 
source and references to other relevant studies). Data extraction was also 
undertaken and discussed between two researchers (AML and VGC), and 
discrepancies resolved by a third researcher (EG).  
A single extraction table was completed to avoid the duplication of the 
impact of various papers reporting the same EE study in the systematic 
review. The most complete paper was chosen to extract the information and 
if any detail about methods or results was missing, it was complemented with 
the second paper. In cases where in the retrieved paper the methods section 
Methods and results 
 66 
 
was incomplete, the referenced effectiveness study or study protocol was 
retrieved to extract the missing information. 
The main outcome variables were the costs incurred and outcomes of 
the PPS and the UC, and the primary outcome or summary measure was the 
incremental cost-effectiveness ratio (ICER) of the PPS compared with UC. 
When the incremental analysis was not provided in the original studies, we 
estimated the ICER when statistically significant differences were found in 
the effectiveness of the PPS vs. UC. Cost-effectiveness results of these 
studies were treated separately. 
The “Suggested risk of bias criteria for EPOC reviews”58 tool was used 
to assess the risk of bias of the RCT/c-RCT, whereas the “Evers’ Checklist”59 
was used to assess the EE. In the studies where a decision analytic model was 
used to extrapolate the short-term results obtained in the RCT/c-RCT to 
long-term results, the “Phillips’ checklist”60 was additionally used to assess the 
model. The study was classified as high quality if there was low risk of bias in 
                                                 
58 Cochrane. EPOC Guidance on Risk of Bias. EPOC. Suggested risk of bias criteria for 
EPOC reviews. UK. Available from: 
https://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/Suggested%20risk%20of
%20bias%20criteria%20for%20EPOC%20reviews.pdf. [Accesed 11 May 2016]. 
59 Evers S, Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of 
methodological quality of economic evaluations: Consensus on Health Economic Criteria. Int 
J Technol Assess Health Care. 2005;21(2):240-5. 
60 Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S. Review of guidelines for good 
practice in decision-analytic modelling in health technology assessment. Health Technol 
Assess. 2004;8(36):1-158. 
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at least 6 criteria of the “Suggested risk of bias criteria for EPOC reviews” 
tool; it was classified as low quality if the risk of bias was high in at least 5 
criteria; the other situations were considered medium quality. The EE was 
classified as high quality if at least 75% of Evers’ (all the papers) and 75% of 
Philips’ criteria (only in decision analytic models) were fulfilled. If less than 
50% of criteria were fulfilled it was classified as low quality, and between 
51%-74% were classified as medium quality. If any criterion was not 
applicable in individual studies, it was not taken into account when calculating 
the percentage. When the score in the risk of bias and the quality of the EE 
was different, the lowest classification was accepted as the overall quality of 
the study. 
To allow direct comparisons across countries and years, costs were 
converted to a common year and currency (USD, 2015 prices) through an 
online tool which uses Purchasing Power Parities (PPP) to convert currencies 
and the Gross Domestic Product deflation index to adjust the years61. The 
PPP values given by the International Monetary Fund were chosen. 
The validity and interpretation of meta-analyses of EE is a widely 
discussed topic mainly due to the low generalisability among health 
                                                 
61 Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target 
currency and price year. Evidence & Policy. 2010;6(1):51-9. 
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systems53,62. Therefore, we synthesized the results through the permutation 
matrix proposed by Nixon et al.63. The matrix shows the nine possible 
outcomes in terms of costs and effectiveness and the shading indicates if the 
decision is strongly or less favoured or if there is no obvious decision. Studies 
were represented in the matrix depending on the ICER point estimates. We 
added a symbol system to indicate the quality of each study when represented 
in the permutation matrix ([+]: low quality, [++]: medium quality and [+++]: 
high quality). 
The protocol of the systematic review was registered in PROSPERO 
(registration number: CRD42016032540) where a detailed protocol of the 
review can be found. 
 
                                                 
62 Anderson R. Systematic reviews of economic evaluations: utility or futility? Health Econ. 
2010;19(3):350-64. 
63 Nixon J, Khan KS, Kleijnen J. Summarising economic evaluations in systematic reviews: a 
new approach. BMJ. 2001;322(7302):1596-8. 
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1.3 Results 
1.3.1 Study selection 
8,314 potential papers were identified through different databases and 
nine through manual searches. After deleting duplicities, 6,902 papers were 
screened using the title and abstract. The 160 papers that met the inclusion 
criteria were assessed in full-text for eligibility. The main exclusion reasons 
were the setting and the study design. Seventeen 
EE38,40,46,64,65,66,67,68,69,70,71,72,73,74,75,76,77 corresponding to 13 studies were included 
                                                 
64 Bernsten C, Bjorkman I, Caramona M, Crealey G, Frokjaer B, Grundberger E, et al. 
Improving the well-being of elderly patients via community pharmacy-based provision of 
pharmaceutical care: a multicentre study in seven European countries. Drugs Aging. 
2001;18(1):63-77. 
65 Bond CM, Fish A, Porteous TH, Reid JP, Scott A, Antonazzo E. A randomised controlled 
trial of the effects of note-based medication review by community pharmacists on prescribing 
of cardiovascular drugs in general practice. Int J Pharm Pract. 2007;15(1):39-46. 
66 Bosmans JE, Brook OH, van Hout HP, de Bruijne MC, Nieuwenhuyse H, Bouter LM, et 
al. Cost effectiveness of a pharmacy-based coaching programme to improve adherence to 
antidepressants. Pharmacoeconomics. 2007;25(1):25-37. 
67 Community Pharmacy Medicines Management Project Evaluation Team. The MEDMAN 
study: a randomized controlled trial of community pharmacy-led medicines management for 
patients with coronary heart disease. Fam Pract. 2007;24(2):189-200. 
68 Jodar-Sanchez F, Malet-Larrea A, Martin JJ, Garcia-Mochon L, Lopez Del Amo MP, 
Martinez-Martinez F, et al. Cost-utility analysis of a medication review with follow-up service 
for older adults with polypharmacy in community pharmacies in Spain: the conSIGUE 
program. Pharmacoeconomics. 2015;33(6):599-610. 
69 Krass I, Armour C, Taylor S, Mitchell B, Brillant M, Stewart K et al. Pharmacy Diabetes 
Care Program. Final Report. The University of Sydney. Australia, 2005. Available from: 
http://6cpa.com.au/wp-content/uploads/Pharmacy-Diabetes-Care-Program-final-
report.pdf. [Accessed April 18, 2016]. 
70 McLean W, Gillis J, Waller R. The BC Community Pharmacy Asthma Study: A study of 
clinical, economic and holistic outcomes influenced by an asthma care protocol provided by 
specially trained community pharmacists in British Columbia. Can Respir J. 2003;10(4):195-
202. 
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since the economic analysis of the MEDMAN study67,72, the conSIGUE 
Program46,68, the PHARMACOP-intervention76,77 and a multicentre study 
carried out in seven European countries64,74 were published in two different 
papers (Figure 2). 
 
                                                                                                                          
71 Rubio-Valera M, Bosmans J, Fernandez A, Penarrubia-Maria M, March M, Trave P, et al. 
Cost-effectiveness of a community pharmacist intervention in patients with depression: a 
randomized controlled trial (PRODEFAR Study). PLoS One. 2013;8(8):e70588. 
72 Scott A, Tinelli M, Bond C, Community Pharmacy Medicines Management Evaluation 
Team. Costs of a community pharmacist-led medicines management service for patients with 
coronary heart disease in England: healthcare system and patient perspectives. 
Pharmacoeconomics. 2007;25(5):397-411. 
73 Simpson SH, Johnson JA, Tsuyuki RT. Economic impact of community pharmacist 
intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk 
intervention by pharmacists. Pharmacotherapy. 2001;21(5):627-35. 
74 Sturgess IK, McElnay JC, Hughes CM, Crealey G. Community pharmacy based provision 
of pharmaceutical care to older patients. Pharm World Sci. 2003;25(5):218-26. 
75 RESPECT Trial Team. Cost-effectiveness of shared pharmaceutical care for older patients: 
RESPECT trial findings. Br J Gen Pract. 2010;60(570):e20-7. 
76 van Boven JF, Tommelein E, Boussery K, Mehuys E, Vegter GS, Brusselle GG, et al. 
Optimalisation de la pharmacothérapie en pharmacie d’officine chez des patients atteints de 
Bronchopneumopathie Chronique Obstructive (BPCO): une analyse coût-efficacité. J Pharm 
Belg. 2014;96(3):15-6. 
77 van Boven JF, Tommelein E, Boussery K, Mehuys E, Vegter S, Brusselle GG, et al. 
Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-
effectiveness analysis. Respir Res. 2014;15:66. 
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WOS: Web of Science; CRD: Centre for Reviews and Dissemination databases; PPS: 
professional pharmacy service; EE: economic evaluation; RCT/c-RCT: randomized controlled 
trial/cluster randomized controlled trial; UC: usual care. 
Figure 2: Flow diagram of the search, screening, excluded and included articles 
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Records after duplicates removed 
(n = 6,902) 
Records excluded 
(n = 6,742)  
Full-text articles excluded  
(n = 143)* 
Not PPS (n=13) 
Not exclusively pharmacist 
in community pharmacy 
(n=49) 
Not full EE (n=26) 
Not main costs (n=2) 
Short-term data not 
gathered from RCT/c-RCT 
(n=91) 
Not PPS vs UC (n=2) 
Type of report (n=16) 
Not Latin alphabet (n=2) 
 
17 papers of 13 studies 
included in the systematic 
review 
MEDLINE 
(n=2,772) 
WOS 
(n=1,717) 
SCOPUS 
(n= 2,453) 
Cochrane 
Library 
(n= 1,085) 
CRD 
Databases 
(n= 287) 
Manual 
searches 
(n= 9) 
(Papers may have been 
excluded due to more than 
one criterion) 
Full-text articles assessed 
for eligibility 
(n = 160) 
Records screened 
(n =  6,902) 
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1.3.2 Characteristics of individual studies 
Thirteen individual studies were included in the systematic review 
(Table 2). Nine (69%) studies were conducted in Europe, two in North 
America (Canada) and two in Australia. Publication years range from 2001 to 
2015. Seven (54%) of the EE were based on a RCT, four (31%) in a c-RCT, 
one was a combination of c-RCT and RCT and one a randomised multiple 
interrupted time-series. This study was included since it compares groups 
randomised by clusters and therefore shares the main characteristics of c-
RCTs. The follow-up period was one year or longer for five of the studies 
(38%), and less than one year in the remaining eight studies (62%). The time 
horizons of the EE were the same as the randomised controlled trial follow-
up length except for three studies extrapolating beyond these periods by 
modelling techniques40,69,77. 
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Table 2: Characteristics and results of the studies 
Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
Compliance, Adherence and/or Concordance services 
Bosmans 
et al66 
Cost 
effectiveness of 
a pharmacy-
based coaching 
programme to 
improve 
adherence to 
antidepressants, 
2007. 
The 
Netherlands 
RCT 
151 
patients 
(IG: 70; 
CG: 81) 
IG: 1st visit: 
pharmacists gave 
information 
about the use of 
antidepressants 
(verbal, written, 
video). Two 
additional visits 
to stimulate 
adherence and 
evaluate safety 
and effectiveness 
of the treatment. 
CG: UC 
 
Study 
follow-up: 6 
months 
EE time 
horizon:  
6 months 
Clinical outcomes:  
Adherence: IG: 88%, 
CG: 86%; (p>0.05). 
Diff. between groups 
in depressive 
symptoms: -0.15; 
p>0.05).  
Humanistic outcomes: 
NA 
Currency, year: €, 2002 
Perspective: Societal 
Included costs:  
Direct medical costs: 
intervention and UC, 
primary and secondary care, 
medication, alternative 
therapies, company doctor. 
Indirect costs: productivity 
losses 
Total cost per patient: IG: 
€3,275 ($4,616); CG: €2,961 
($4,173); (p>0.05). 
 
Type of EE: 
CEA 
Incremental 
analysis: €149 
($210)/1% 
improvement in 
adherence 
€2,550 
($3,594)/point 
improvement in 
the SCL 
depression mean 
item score 
Elliott 
et al 38 
The cost 
effectiveness of 
a telephone-
based pharmacy 
advisory service 
to improve 
adherence to 
newly 
prescribed 
medicines, 
2008. 
RCT 
492 
patients 
(IG: 255; 
CG: 237) 
IG: Pharmacists 
made a semi 
structured interview 
by phone, enquiring 
about medicine 
related problems and 
adherence to the new 
medicine. 
CG: UC 
Study 
follow-up: 2 
months 
EE time 
horizon:  
2 months 
Clinical outcomes: 
Non-adherence: 
IG: 10/87, 11%. 
CG: 23/118, 19% 
(p<0.05) 
Humanistic 
outcomes: NA 
Currency, year: £, 
2004/2005 
Perspective: Healthcare 
system 
Included costs:  
Direct medical costs: 
intervention (time of 
pharmacists, call tariff), GP 
and ED visits, outpatient, 
hospitalisations. 
Total cost per patient: IG: 
Type of EE: CEA 
Incremental 
analysis: The 
intervention is 
dominant 
(cost/extra 
adherent patient) 
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Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
United 
Kingdom 
 
£188 ($347); CG: £283 
($523); (p<0.05). 
 
Rubio-
Valera 
et al 71 
Cost-
Effectiveness of 
a Community 
Pharmacist 
Intervention in 
Patients with 
Depression: A 
Randomized 
Controlled Trial 
(PRODEFAR 
Study), 2013. 
Spain 
RCT 
179 
patients 
(IG: 87; 
CG: 92) 
IG: Intervention 
when patients 
picked up their first 
prescription of 
antidepressants, + 
reminder when 
refilling 
prescriptions. 
Focused on 
antidepressants, 
compliance, side-
effects and carrying 
out GPs’ advice. 
CG: UC 
Study 
follow-up: 6 
months 
EE time 
horizon:  
6 months 
Clinical outcomes: 
Diff. between groups 
in adherence: 0.04 
(p>0.05), severity of 
depression: -0.01 
(p>0.05). 
Humanistic outcomes: 
Diff. between groups 
in QALY: 0.01 
(p>0.05) (EQ-5D). 
Currency, year: €, 2009 
Perspective: Societal and 
healthcare system 
Included costs:  
Direct medical costs: 
intervention (training of 
pharmacists, pharmacy 
time), medication, 
diagnostic tests, ED 
visits, hospital 
admissions, other visits 
to primary and 
secondary care. 
Indirect costs: sick 
leave (only in societal 
perspective). 
Total cost per patient: 
IG: €1,091 ($1,547); CG: 
€767 ($1,088); (p>0.05). 
 
Type of EE: CEA 
and CUA 
Incremental 
analysis: 
Societal 
perspective: 
€1,866 
($2,647)/adherent 
patient  
€9,872 
($14,002)/QALY  
Healthcare 
perspective: 
€962 
($1,364)/adherent 
patient 
€3,592 
($5,095)/QALY 
*Cost/depressive 
symptoms: UC 
dominated the 
intervention. 
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Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
van 
Boven 
et al 77 
Improving 
inhaler 
adherence in 
patients with 
Chronic 
Obstructive 
Pulmonary 
Disease: a 
cost-
effectiveness 
analysis, 2014. 
Belgium 
RCT 
734 
patient 
(IG: 371; 
CG: 363) 
IG: Visit 1: 
structured education 
about COPD 
pathophysiology, 
medication, self-
management and 
smoking cessation 
(written+verbal). 
Visit 2: verbal 
reminder of the 
education provided 
in visit 1. 
CG: UC 
Study 
follow-up: 3 
months 
EE time 
horizon:  
12 months 
Clinical outcomes:  
Hospital-treated 
exacerbation: IG: 
0.177/patient; CG: 
0.244/patient (p<0.05). 
Humanistic outcomes: 
Diff. between groups 
in QALY less than 
0.001 (p>0.05) (EQ-
5D). 
Currency, year: €, 2013 
Perspective: Healthcare 
system 
Included costs: Direct 
medical costs: 
intervention (training 
and pharmacy time), 
medication, 
community/ED/hospita
l treated exacerbation. 
Total cost per patient: 
IG: €2,221 ($2538); CG: 
€2,448 ($2,797); 
(p<0.05). 
Type of EE: CUA 
and CEA 
Incremental 
analysis: 
The intervention is 
dominant 
(Cost/QALY and 
cost/hospital 
treated 
exacerbations 
avoided) 
 
Medication Therapy Management services 
Bernsten 
et al 64 
Improving the 
well-being of 
elderly patients 
via community 
pharmacy-based 
provision of 
pharmaceutical 
care: a 
multicentre 
study in seven 
European 
countries, 2001. 
Denmark, 
c-RCT 
190 
pharmacies 
(IG: 104; 
CG: 86) 
2,454 
patients 
(IG: 1290; 
CG: 1164) 
IG: Pharmacists 
identified drug-
related 
problems and 
formulated an 
intervention + 
monitoring 
plan. Education 
on drug regimen 
and medical 
conditions, 
compliance-
improving 
Study 
follow-up: 
18 months 
EE time 
horizon: 
cost data 
given for 3 
periods of 6 
months 
Clinical outcomes: 
Hospitalisations: IG: 
35.6% of patients and CG: 
40.4% reported one or 
more hospitalisations 
(p>0.05). 
Clinical Signs and 
Symptom Control: better 
control within IG (diff. 
between groups not 
given). 
Knowledge of 
medicines, compliance, 
Currency, year:  
€, 1999 
Perspective: 
Healthcare system (not 
given in the paper) 
Included costs:  
Direct medical costs: 
intervention (pharmacy 
time), medication, 
hospitalisations, 
GP/specialists/nurse 
visits. 
Total cost per patient: 
Type of EE: 
Cost-
consequence 
analysis. 
Incremental 
analysis: 
NA (no 
differences in 
effectiveness 
were assumed) 
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Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
Germany, The 
Netherlands, 
Northern 
Ireland, 
Portugal, 
Republic of 
Ireland and 
Sweden 
strategies and 
rationalising 
drug regimens 
(with GP). 
Continuous 
visits. 
CG: UC 
 
contacts with GP, drug 
use and number of 
changes in therapy: 
overall, p>0.05 between 
groups.  
Humanistic outcomes:  
Health-related quality of 
life: no differences 
between groups (p<0.05) 
(SF-36). Patient 
satisfaction: some 
indicators higher in IG. 
 
IG: €19,212 ($40,054); 
CG: € 21,480 ($44,782) 
(estimated by reviewers). 
 
Bojke 
et al 75 
Cost-
effectiveness of 
shared 
pharmaceutical 
care for older 
patients: 
RESPECT trial 
findings, 2010. 
United 
Kingdom 
Randomised 
multiple 
interrupted 
time-series 
Patients: 760 
5 primary 
care trusts 
 
IG: 
Medication 
review 
focused on 
appropriate 
prescription 
and use. 
Collaboration 
among 
pharmacist, 
patient and 
GP. Drug 
related 
problems are 
resolved 
through 
continuous 
Study 
follow-up: 
12 months 
EE time 
horizon:  
12 months 
Clinical outcomes: NA 
Humanistic outcomes: 
Utility scores: Highest 
scores obtained in 
intervention months; IG: 
0.614; CG: 0.595; 
p>0.05) (EQ-5D). 
Currency, year: £, 2004-
2005 
Perspective: 
Healthcare system  
Included costs:  
Direct medical costs: 
Intervention (pharmacy 
time), medications 
(acute+ repeat), 
laboratory tests, visits to 
the general practice/ 
primary care 
clinic/home visits and 
telephone consultations 
(GP/nurse), outpatient 
and inpatient 
admissions. 
Type of EE: CUA 
Incremental 
analysis: £10,000 
($18,507)/QALY 
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Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
visits. 
CG: UC 
Total cost per patient: 
IG: £2,001 ($3,703); CG: 
£1,809 ($3,348); 
(p>0.05). 
 
Bond et 
al a 67 
The MEDMAN 
study: a 
randomized 
controlled trial of 
community 
pharmacy-led 
medicines 
management for 
patients with 
coronary heart 
disease, 2007. 
United Kingdom 
RCT 
1493 
patients (IG: 
980; CG: 
513) 
IG: Initial 
consultation + 
follow-up 
visits. 
Consultations 
included 
assessments of 
therapy, 
medication 
compliance, 
lifestyle and 
social support. 
Recommendat
ions sent to 
GP. 
CG: UC 
Study 
follow-up: 
12 months 
EE time 
horizon:  
12 months 
Clinical outcomes: 
Proportion of patients 
receiving secondary 
prevention treatment 
for CHD/ cumulative 
score summarizing 
‘appropriate treatment’ 
and advice/adherence: 
no differences between 
groups. 5-year risk of 
CV death: slightly better 
IG (p>0.05). 
Humanistic outcomes:  
SF-36 and EQ-5D 
scores: no differences 
between groups. 
Patient satisfaction: 
IG: 46.0; CG: 43.0; 
(p<0.01). 
 
Currency, year: £, 
2003/2004 
Perspective: 
Healthcare system (and 
patient) 
Included costs:  
Direct medical costs: 
Intervention (training of 
pharmacists, pharmacy 
time), medicines, CHD 
related hospital visits/GP 
visits/ nurse visits. 
Total cost per patient: IG: 
£1,433 ($2,704); CG: 
£1,286 ($2,426); (p<0.05). 
 
Type of EE: 
CMA 
Incremental 
analysis: 
NA 
Bond 
et al  
b 65 
A randomised 
controlled trial of 
the effects of 
note-based 
medication review 
RCT 
2014 
patients 
(Angina 
group: IG: 
IG: 
Pharmacists 
conducted a 
single review 
of the 
Study 
follow-up: 
12 months 
EE time 
horizon:  
Clinical outcomes:  
Quality of 
prescribing/appropriat
eness of medication: 
more IG patients were 
Currency, year:  
£, 1999 
Perspective: Healthcare 
system (not given) 
Included costs:  
Type of EE: 
Cost-
consequence 
analysis. 
Incremental 
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Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
by community 
pharmacists on 
prescribing of 
cardiovascular 
drugs in general 
practice, 2007. 
United Kingdom 
340, CG: 
366. 
Hypertensio
n group: IG: 
656, CG: 
652). 
patient’s 
medical 
records, and 
recommended 
changes to 
GP. 
CG: UC  
12 months 
(not given) 
ordering antiplatelet 
drugs after the 
intervention (diff. 
between groups = 7.6% 
(p<0.05).  
For angina patients only: 
More patients in CG 
made fewer visits to an 
outpatient department 
for CVD-related 
reasons and to GP 
surgery for CVD-
related reasons. More 
patients in IG received 
fewer home visits for 
CVD-related reasons. 
Humanistic outcomes:  
EQ-5D scores: no 
differences between 
groups. 
 
Direct medical costs: 
intervention (pharmacy 
time), hospital admissions, 
home visits, 
outpatient/surgery 
attendance, tests, 
prescribing costs. 
Total cost per patient: IG: 
£230 ($480); CG: £187 
($390) 
(estimated by reviewers) 
analysis: 
£4.8 ($10)/ 
patient with 
history of 
myocardial 
infarction 
ordering an 
antiplatelet 
(estimated by 
reviewers) 
Jódar-
Sánchez 
et al 68 
Cost-Utility 
Analysis of a 
Medication 
Review with 
Follow-Up 
Service for 
Older Adults 
with 
Polypharmacy 
c-RCT 
1403 
patients (IG: 
688; CG: 
715) 
178 
pharmacies 
(IG: 88; CG: 
90) 
IG: 
comprehensiv
e medication 
review in 
which the 
pharmacist 
identifies drug 
related 
problems and 
Study 
follow-up: 6 
months 
EE time 
horizon:  
6 months 
Clinical outcomes:  
Number of medicines: 
greater reduction in IG 
(diff. between groups: 
0.21; p>0.05).  
ED visits: reductions in 
IG (before-after: 
p<0.05).  
Number of hospital 
Currency, year: €, 2014 
Perspective: 
Healthcare system 
Included costs: Direct 
medical costs: 
Intervention (pharmacy 
time, training of 
pharmacists, investment of 
the community pharmacy), 
Type of EE: 
CUA 
Incremental 
analysis: 
The intervention 
is dominant 
(Cost/QALY) 
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Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
in Community 
Pharmacies in 
Spain: The 
conSIGUE 
Program, 2015. 
Spain 
agrees an 
action plan 
with patient 
and GP if 
required. 
Continuous 
visits. 
CG: UC 
admissions: IG: 0.03; 
CG: 0.06 (p<0.05). 
Humanistic outcomes: 
significant improvement 
in IG compared to CG 
(diff. between groups: 
0.055 in utility score 
(p<0.05) and 5.87 in 
VAS score (p<0.05) 
(EQ-5D). 
medication, ED visits, 
medication-related 
hospital admissions. 
Total cost per patient: IG: 
€978 ($1,364); CG: €1,173 
($1,638) (p>0.05). 
Disease State Management for Chronic Conditions services 
Gordois 
et al 40 
Cost-
Effectiveness 
Analysis of a 
Pharmacy 
Asthma Care 
Program in 
Australia, 2007. 
Australia 
c-RCT 
396 
patients 
(IG: 191; 
CG: 205) 
57 
pharmaci
es (IG: 
29; CG: 
28) 
IG: Education on 
asthma, 
medication, 
lifestyle, inhaler 
technique, 
adherence and 
detection of 
drug‐related 
problems. Referral 
to a GP as 
appropriate. 
Continuous visits. 
CG: UC 
Study 
follow-up: 6 
months 
EE time 
horizon:  
5 years 
Clinical outcomes: 
Healthcare use 
resources: 
No differences 
between groups 
(p>0.05). 
Humanistic outcomes:  
Six month study: 0.008 
QALY/patient gained 
in IG. When modelling 
to 5 years, 0.131 
QALYs are gained in 
IG compared to CG 
(p>0.05 mild and 
moderate asthma; 
p<0.05 severe asthma) 
(AQoL questionnaire). 
Currency, year: AUD, 
2006 
Perspective: Healthcare 
system 
Included costs: Direct 
medical costs: 
intervention (pharmacy 
time, spirometers and 
consumables, software, 
promotional material, 
training resources), asthma 
medication, GP/ED visits, 
hospital admissions. 
Total cost per patient: 
Annual review scenario: 
IG: AUD 2,136 ($1,760); 
CG: AUD 1,514 ($1,248). 
Type of EE: 
CUA 
Incremental 
analysis: 
Annual review 
scenario: AUD 
4,753 
($3,918)/QALY 
No annual review 
scenario: AUD 
2,869 
($2,365)/QALY 
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Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
 No annual review 
scenario: IG: AUD 1,890 
($1,557); CG: AUD 1,514 
($1,248). 
 
Krass et 
al 69 
Pharmacy 
Diabetes Care 
Program. Final 
Report, 2005. 
Australia 
c-RCT 
335 
patients 
(IG: 176; 
CG: 159) 
58 
pharmaci
es 
IG: Pharmacists 
recorded patients’ 
information and 
provided targeted 
counselling. 
Topics: lifestyle, 
blood glucose 
monitoring, 
adherence, 
reminders of 
follow-up checks 
for complications 
related to diabetes 
medicines. 
Continuous visits. 
CG: UC 
Study 
follow-up: 6 
months 
EE time 
horizon:  
10 years  
Clinical outcomes:  
HbA1c: IG: -0.97%; 
CG: -0.27%; p<0.05). 
Blood pressure: 
systolic decreased 
within IG (p<0.01). 
Lipid profile and 
BMI: no differences 
between groups 
(p>0.05). 
Humanistic outcomes:  
Utility scores: 
improvement from 
0.75 to 0.79 within IG 
(p>0.05). CG: no 
changes (data at 6 
months) (EQ-5D). 
 
Currency, year: AUD, 
2004 
Perspective: Healthcare 
system 
Included costs:  
Direct medical costs: 
intervention (counter 
display unit, blood 
pressure monitor + 
software, pharmacists’ 
fees, printouts, 
telephone calls), 
medication, GP, 
hospitalisations. 
Total cost per patient: 
IG: AUD 10,512 
($9,499); CG: AUD 
7,148 (6,459); (p<0.05). 
 
Type of EE: CUA 
and CEA 
Incremental 
analysis: 
Scenario A (0.35% 
HbA1c reduction) 
AUD 24,029 
($21,714) /LYG 
AUD 30,582 
($27,636) /QALY 
Scenario B (0.70% 
HbA1c reduction): 
AUD 17,752 
($16,042)/LYG 
AUD 22,486 
($20,320) /QALY 
McLean 
et al 70 
The BC 
Community 
Pharmacy 
Asthma Study: 
A study of 
clinical, 
Combina
tion of a 
RCT and 
c-RCT 
405 
patients 
IG: Teaching of 
asthma self-
management: 
disease, 
medications, trigger 
identification and 
Study 
follow-up: 
12 months 
EE time 
horizon:  
12 months 
Clinical outcomes:  
Peak expiratory flow 
rate/ Symptoms: 
better results in IG 
than CG (p<0.05). 
Medical visits: 
Currency, year: CAD, 
1998 (not given) 
Perspective: Societal (not 
given) 
Included costs: Direct 
medical costs: 
Type of EE: 
Cost-
consequence 
analysis. 
Incremental 
analysis:  
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Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
economic and 
holistic 
outcomes 
influenced by an 
asthma care 
protocol 
provided by 
specially trained 
community 
pharmacists in 
British 
Columbia, 2003. 
Canada 
(IG: 191; 
CG: 214) 
27 
pharmaci
es 
avoidance. 
Development of 
asthma action plan. 
A comprehensive 
first visit + follow-
up visits. 
CG: UC 
(not given) decrease in IG and 
increase in CG 
(p<0.05). 
School or work days 
off, ED visits and 
hospitalisations: no 
differences between 
groups.  
Drug utilization: 
significant drop in 
beta-agonist use in IG, 
no changes in 
corticosteroids. 
Humanistic outcomes:  
QoL (Juniper 
questionnaire) 
/Knowledge: greater 
increase in IG 
(p<0.01). 
 
intervention (pharmacist 
fees), medical visits, ED 
visits, hospitalisations, 
prescription drugs. 
Indirect costs: days off 
from school or work 
Total cost per patient: IG: 
CAD 150 ($179); CG: 
CAD 351 ($418) 
 
The intervention 
is dominant 
(Cost/peak 
expiratory flow 
rate (L/min), 
estimated by 
reviewers) 
Simpson 
et al 73 
Economic 
Impact of 
Community 
Pharmacist 
Intervention in 
Cholesterol Risk 
Management: 
An Evaluation 
of the Study of 
Cardiovascular 
RCT 
675 
patients 
(IG: 344; 
CG: 331) 
IG: Screening and 
identification of 
CVD risk factors, 
individualised 
education on risk 
factor management 
(verbal + written), 
referral GPs. 
Continuous visits. 
CG: UC 
Study 
follow-up: 4 
months 
EE time 
horizon:  
4 months 
Clinical outcomes:  
Number of 
cholesterol tests: IG: 
182 and CG: 96. 
Number of 
cholesterol-lowering 
drugs: IG: 34 and CG: 
14. 
Humanistic outcomes: 
NA 
Currency, year: CAD, 
1999 
Perspective: Provincial 
government (and 
community pharmacy 
managers) 
Included costs: Direct 
medical costs: 
intervention, physician 
visits, cholesterol-lowering 
Type of EE: 
Cost-
consequence 
analysis. 
Incremental 
analysis: 
CAD 1.4 
($1.6)/new 
prescription of 
cholesterol-
 82 
 
Author Title, 
year, 
country 
Study design, 
sample size 
Intervention and 
control group 
description 
Follow-up 
and time 
horizon 
Clinical and 
humanistic outcomes 
assessed 
Cost data reported Cost and 
consequence 
(USD, 2015) 
Risk 
Intervention by 
Pharmacists, 
2001. 
Canada 
 medication, cholesterol 
profile tests, liver function 
test, ED visits. 
Total cost per patient: IG: 
CAD 56 ($66); CG: CAD 
28 ($33) (estimated by 
reviewers) 
lowering drugs 
(estimated by 
reviewers) 
RCT: randomised controlled trial; c-RCT: cluster randomised controlled trial; ED visits: emergency department visits; EQ-5D: EuroQoL-
5D; GP visits: general practitioner visits; EE: economic evaluation; CEA: cost-effectiveness analysis; CUA: cost-utility analysis; CMA: cost-
minimisation analysis; QALY: quality adjusted life years; LYG: life years gained; IG: intervention group; CG: comparison group; UC: usual 
care; NA: not applicable; BMI: body mass index; CV(D): cardiovascular (disease); HbA1c: glycated haemoglobin; VAS: visual analogue scale; 
CAD: Canadian dollars; AUD: Australian dollars; USD: United States dollars. 
 
 83 
 
1.3.3 Professional pharmacy services 
The service was always provided during a face to face interaction in the 
pharmacy, with the exception of one telephone-based study38. Nine (69%) of 
the studies were focused on patients with a single disease such as 
depression66,71, type 2 diabetes69, respiratory conditions40,70,77 and 
cardiovascular diseases65,67,73. Other services were targeted at elderly using 
polypharmacy64,68,75 and patients with one or more chronic conditions38. 
All the studies were classified in three of the nine categories considered 
in the hierarchical model. “Compliance, Adherence and/or Concordance” 
interventions were provided in four (31%) of the studies38,66,71,77. All of them 
where delivered to patients with a newly prescribed medication. Five (38%) 
studies assessed “medication therapy management services”64,65,67,68,75. Four of 
them were medication review with follow-up services64,67,68,75 and the fifth 
service provided did not have follow-up65. Four (31%) services were “Disease 
state management for chronic conditions”40,69,70,73. Gordois et al40  and Krass et 
al69 assessed very similar services, provided in the same country (Australia), 
with a similar study design and economic evaluation. The most important 
characteristics of the services are described in Table 2.  
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1.3.4 Details of economic evaluations 
The perspective was stated in ten (77%) of the studies and it was 
identifiable using the costs included in the remaining studies64,65,70. Nine (69%) 
of the evaluations were performed from the healthcare system perspective, 
two from the societal, one from the government  and one from both the 
societal and the healthcare system (Table 2). 
Some studies did not include potentially important cost components 
such as the cost of pharmacists’ training40,64,65,75 or general practitioner (GP) 
visits68. Additionally, a wide range of direct medical cost components were 
self-reported. In some studies all the costs were self-reported by patients69,70,80, 
whereas in other studies some costs were self-reported by patients and some 
costs were extracted from the pharmacy and medical or hospital 
records64,67,68,71,73,77. Other studies did not clearly state how they retrieved this 
information40,65,66. The sources used for the cost valuation in all the studies 
were mainly official data of the country where the study was undertaken.  
An incremental analysis was performed in nine (69%) studies: three 
studies performed a cost-utility analysis (CUA)40,68,75, two studies performed a 
CEA38,66 , three studies performed both CUA and CEA69,71,77 and one study 
reported a cost-minimisation analysis (CMA)67. All of them used outcome 
Methods and results 
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indicators to calculate ICERs. The remaining four studies were presented as 
cost-consequence analysis, and we estimated the incremental analyses. 
Outcome indicators were available in two studies65,70 and only process 
indicators in the remaining one73. We decided not to calculate an incremental 
analysis in the study published by Bernsten et al64 due to the lack of 
statistically significant difference in effectiveness between study groups. The 
clinical significance of some indicators was higher than others (i.e. “extra 
adherent patient”38,71 vs. “1% improvement in adherence”66). 
1.3.5 Risk of bias and quality of economic evaluations 
The overall quality assessment yielded seven studies of high, three of 
medium and three of low quality (Table 3). According to the study design, the 
evidence level provided by all the studies was high (RCT/c-RCT). Seven 
studies had low risk of bias40,67,68,69,71,75,77, whereas two studies had high risk of 
bias65,70. The most frequent high risk of bias was the risk of contamination 
bias among RCTs and the lack of reporting baseline characteristics of control 
and intervention providers among c-RCTs. The risks of bias related to the 
randomisation (allocation sequence and concealment) were low in all the 
studies.  
Experimental design and results 
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The methodological quality of the EE assessed by Evers’ checklist 
applied to all the EE, ranged from 39%73 to 95%77 with a mean score of 73%. 
The item “Are all future costs and outcomes discounted appropriately?” was 
not applicable to several studies as the time horizon did not exceed one year. 
None of the studies fulfilled the item “Are ethical and distributional issues 
discussed appropriately?” The methodological quality of the three decision 
analytic models40,69,77 according to Philips’ list was 87% in average. The EE 
carried out by van Boven et al77 scored the highest punctuations in both 
Evers’ and Philips’ assessment tools. 
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Table 3: Quality assessment of the studies 
Study Risk of biasa Quality of the EEb Overall 
qualityc Evers Philips  
Bojke  
et al 75 
Low risk: 7 
High risk: 1 
Unclear risk: 1 
High 15/18 = 83% NA High High 
Bond  
et al a 67 
Low risk: 8 
High risk: 1 
Unclear risk: 0 
High 14/18 = 78% NA High High 
Gordois 
et al 40 
Low risk: 7 
High risk: 1 
Unclear risk: 1 
High 16/19 = 84% 41/48 = 85% High High 
Jodar-
Sanchez 
et al 68 
Low risk: 7 
High risk: 1 
Unclear risk: 1 
High 15/18 = 83% NA High High 
Krass  
et al 69 
Low risk: 7 
High risk: 0 
Unclear risk: 2 
High 15/19 = 79% 38/47 = 80% High High 
Rubio-
Valera  
et al 71 
Low risk: 7 
High risk: 2 
Unclear risk: 0 
High 16/18 = 89% NA High High 
van 
Boven  
et al 77 
Low risk: 6 
High risk: 2 
Unclear risk: 1 
High 18/19 = 95% 45/47 = 96% High High 
Bosmans 
et al 66 
Low risk: 5  
High risk: 4 
Unclear risk: 0 
Medium 15/18 = 83% NA High Medium 
Bernsten 
et al 64 
Low risk: 3 
High risk: 4 
Unclear risk: 2 
Medium 10/18 = 55% NA Medium Medium 
Elliott  
et al 38 
Low risk: 4 
High risk: 2 
Unclear risk: 3 
Medium 13/18 = 72% NA Medium Medium 
McLean 
et al 70 
Low risk: 4 
High risk: 5 
Unclear risk: 0 
Low 11/18 = 61% NA Medium Low 
Simpson 
et al 73 
Low risk: 3 
High risk: 4 
Unclear risk: 2 
Medium 7/18 = 39% NA Low Low 
Bond  
et al b 65 
Low risk: 4 
High risk: 5 
Unclear risk: 0 
Low 8/18 = 44% NA Low Low 
aRisk of bias: High quality: low risk ≥6; Low quality: high risk ≥ 5; Medium quality: others. bQuality 
of EE: High quality: ≥75%; Low quality: ≤50%; Medium quality: 51%-74% (Evers’ checklist was 
used to assess all the EE, and additionally Philips’ checklist in decision analytic models). cOverall 
quality: the study was classified with the lowest level of quality scored among all the assessments. 
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1.3.6 Cost-effectiveness of interventions 
The cost-effectiveness of PPSs compared with UC is shown in the 
permutation matrix (Figure 3). 
More effective and less costly interventions: 
The intervention assessed was found to be dominant in four 
studies38,68,70,77. The permutation matrix showed that the decision of accepting 
these interventions was strongly favoured. 
An incremental analysis was performed in three of the studies38,68,77. All 
of them found statistically significant improvements in the IG for humanistic 
and/or clinical outcomes, with lower associated costs. The uncertainty 
surrounding the ICER, represented by the cost-effectiveness plane and cost-
effectiveness acceptability curves, was low. This is due to the probability for 
the services to be cost-effective at a willingness to pay (WTP) of $0 per unit 
of effectiveness was higher than 90% in the three studies. Specifically, 
probabilities were 96% at a WTP of €0 per QALY68, 90% at a WTP of £0 per 
extra adherent patient38, and 99.4% at a WTP of €0 per QALY77. The 
dominant situation of the intervention was retained in all the univariate, 
scenario and probabilistic sensitivity analyses performed by van Boven et al77.
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 INCREMENTAL EFFECTIVENESS   
IN
C
R
E
M
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N
T
A
L
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O
S
T
S
 
 - 0 +   
+
 
A 
 
 
B 
 
Bond, 2007 a67 [+++] 
C 
 
Gordois, 200740 [+++] 
Rubio-Valera, 201371 [+++] 
Bojke, 201075 [+++] 
Krass, 200569 [+++] 
Bosmans, 200766 [++] 
Simpson, 200173 [+] 
Bond, 2007 b65 [+] 
 
 0
 
D E F  
- 
G H 
 
Bernsten, 200164 [++] 
 
I 
 
Jodar-Sanchez, 201568 
[+++] 
van Boven, 201477 [+++] 
Elliott, 200838 [++] 
McLean, 200370 [+] 
 
 
 Decision strongly favoured (A, reject intervention / I, accept intervention) 
 
 Decision less favoured (B, D, reject intervention / F, H, accept intervention) 
 
 No obvious decision (C, is added effect worth added cost?/G, is reduced effect acceptable 
given reduced cost?/E, neutral cost and effect. Other reasons to adopt intervention?) 
 
Effectiveness: +better, 0 same, - poorer; costs: + higher, 0 same, - lower. [+++]: high quality 
study; [++]: medium quality study; [+]: low quality study. 
Figure 3: Permutation matrix summarising incremental cost and effectiveness 
findings of economic evaluations for professional pharmacy services in community 
pharmacy vs. usual care 
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Costs were lower in the IG, largely due to the decrease in 
hospitalisation costs38,68. The quality of the evidence provided by those studies 
was considered high68,77 and medium38. The authors concluded that the 
implementation of the service was recommended or suggested38,68,77. 
McLean et al70 also suggested the implementation of the service, since 
statistically significant improvements were found in IG compared to CG in 
most of the clinical and humanistic indicators at lower costs. The ICER 
calculated by reviewers showed savings of CAD 6.4 ($7.6) per one unit 
improvement in the peak expiratory flow rate (L/min). 
Same effectiveness and less costly interventions: 
Bernsten et al64 assessed several clinical and humanistic outcomes. 
Statistically significant differences were not found between study groups and 
costs were lower in IG. Reviewers decided to assume equal effectiveness 
between both alternatives with less cost in IG, and we could not assess 
uncertainty. Although the decision of accepting or rejecting this intervention 
was less favoured, it should be accepted. 
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Same effectiveness and more costly interventions: 
Bond et al a67 only found statistically significant differences in the 
patient satisfaction. Therefore the authors presented a CMA, assuming equal 
effectiveness between the intervention and UC72 and costs were significantly 
higher in IG. The decision of accepting or rejecting this intervention was less 
favoured according to the permutation matrix, but it should be rejected. 
More effective and more costly interventions:  
The decision of accepting or rejecting all these interventions was not 
obvious, and it should be considered if added effect was worth the added 
cost. 
The two studies focused on antidepressants performed the EE from 
the societal perspective66,71. Costs were slightly higher in the IG, and the 
difference was driven by indirect costs. For this reason in the Rubio-Valera et 
al study71 the ICER from the societal perspective was higher than the 
healthcare system perspective (societal perspective: €1,866 ($2,647) per 
adherent patient and €9,872 ($14,002) per QALY; healthcare system 
perspective: €962 ($1,364) per adherent patient and €3,592 ($5,095) per 
QALY). Bosmans et al66 used only the societal perspective and the ICERSs 
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showed €149 ($210) per 1% improvement in adherence and €2,550 ($3,594) 
per point improvement in the Hopkins Symptom Checklist depression mean 
item score. Even though the point estimates of the ICERs/ICUR were not 
high, the implementation of the service was not recommended by the authors 
of both studies due to the high uncertainty evidenced by the cost-
effectiveness plane and cost-effectiveness acceptability curve. In Bosmans et 
al, with a WTP of €1,000 ($1,468) the probability of the service of being cost-
effective was 0.766 and ranged from 0.46 to 0.76 with a WTP ranging from 
€500 ($755) to €30,000 ($45,302) under the different scenarios considered by 
Rubio-Valera et al71.  
Two studies modelled the short-term outcomes achieved in the trials to 
a time horizon of five years through a Markov model40 and to 10 years 
through a similar model69. Krass et al69 found significant reductions in glycated 
haemoglobin (HbA1C) in the IG compared to CG but not in utility scores. 
ICERs and ICURs were presented for two scenarios, depending on the 
reduction of the HbA1C. Results ranged from AUD 17,752 ($16,042) per life 
years gained (LYG) to AUD 30,582 ($27,636) per QALY, with chances of 
being cost-effective ranging from 71% to 93% with a WTP of AUD 50,000 
($47,310). The service was cost-effective in almost all the scenarios studied in 
the one-way sensitivity analysis. The authors concluded that the intervention 
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was cost-effective compared with other healthcare programs that were 
routinely funded by the Commonwealth (interventions below AUD 37,000 
($35,009) to AUD 69,000 ($65,287) per life year). 
Gordois et al40 found that utility scores were significantly higher for 
patients with severe asthma in the IG compared with the CG. ICURs were 
calculated for two scenarios (with/without annual review to maintain the 
improvements in asthma) and ranged between AUD 4,753 ($3,918) per 
QALY and AUD 2,869 ($2,365) per QALY. The ICUR for the 6-month 
study was AUD 64,870 ($53,471) per QALY. The one-way sensitivity analysis 
showed that the cost-effectiveness of the program was sensitive to the time 
horizon and proportion of patients with severe asthma, and best-worst 
scenario that it could range from AUD 576 ($497) to AUD 7,189 ($6,198). 
Authors conclude that the service was cost-effective, and potentially 
implementable in the Australian healthcare system. 
In the EE published by Bojke et al75, the mean utility scores were higher 
during the intervention (IG: 0.614; CG: 0.595; p>0.05). A wide number of 
health service use costs extracted from GP records were included in the 
analysis. The ICUR was considered cost-effective by the authors, based on 
the thresholds of the National Institute for Health and Clinical Excellence 
(NICE) (ICUR: £10,000 ($18,507) per QALY; NICE thresholds: £20,000 
Experimental design and results 
Methods and results 
 94 
 
($35,616) - £30,000 ($53,424) per QALY78). For these thresholds, the 
probability for the service being cost-effective was 0.775 and 0.812 
respectively. 
Simpson et al73 and Bond et al b65 had low scores in quality assessment. 
As they were cost-consequence analysis, we estimated the ICER using the 
intermediate outcomes reported, and the uncertainty was unknown. The 
ICER of Simpson et al was CAD 1.4 ($1.6) per new prescription of 
cholesterol-lowering drugs. The authors suggested that the reimbursement to 
pharmacies for providing this service would be justified. Bond et al b 
measured the quality of prescribing by the appropriateness of medication, and 
it showed significant improvements in the IG group compared to UC. Using 
this indicator the ICER turned out to be £4.8 ($10) per patient with history of 
myocardial infarction using an antiplatelet. The authors concluded that the 
improvements achieved by the intervention were limited, probably due to the 
characteristics of the service, the study being underpowered, or due to 
potential contamination bias as other projects with similar aims were being 
conducted in the same time. 
 
                                                 
78 National Institute for Health and Clinical Excellence. Guide to the methods of technology 
appraisal. London: NICE, 2008. 
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1.4 Discussion 
Thirteen studies were identified and seven were high quality EE based 
on c-RCT with low risk of bias. Two high quality studies provided evidence 
that PPSs delivered in community pharmacy can dominate UC, improving 
patients’ clinical outcomes and health-related quality of life, while saving costs 
to the healthcare system. Four high quality studies suggested, with higher 
uncertainty, that PPSs could improve patients’ outcomes with financial 
investment. The remaining high quality study assumed equal effectiveness 
between the PPS and UC, with the PPS as the most costly alternative. Results 
reported by studies with lower quality and subsequently less reliable 
information were mainly spread between the services being more effective at 
either higher or lower costs. Therefore, even though different outcomes were 
found among studies, an overall trend towards the cost-effectiveness of PPSs 
in community pharmacy could be observed. 
The intervention was cost-effective in those studies in which the 
authors compared their ICURs with a specific cost-utility threshold40,68,69,75. A 
gross analysis without considering the quality of the studies and the 
uncertainty and reliability of the incremental analyses, showed that using the 
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arbitrary but commonly used figure of $50,000 per QALY79, all six ICURs 
were far below the threshold: less than $0 in two of the studies68,77, $2,365- 
$3,91840, $18,50775, $5,095-$14,00271 and $27,63669. In those studies where the 
effectiveness of both alternatives was assumed to be equal, the intervention 
turned out to be either more costly67 or less costly64. The remaining five 
ICERs were calculated using different and therefore incomparable variables; 
however two of them showed savings per one unit of improvement in 
effectiveness38,70 and the maximum investment needed was $3,594 for 
improving one effectiveness unit in the remaining three65,66,73. 
Similar trends have been found in other recent systematic reviews of 
pharmacists providing PPSs in different settings, where services were 
generally considered cost-effective and cost saving41,52. Another review80 
concluded that the poor quality of the studies precluded from finding the 
cost-effectiveness of pharmacists interventions. However, the authors rigidly 
imposed CHEERS guidelines to assess the methodological quality of the 
studies, when CHEERS guidelines were developed to examine the quality of 
                                                 
79 Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY 
threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-78. 
80 Elliott RA, Putman K, Davies J, Annemans L. A review of the methodological challenges in 
assessing the cost effectiveness of pharmacist interventions. PharmacoEconomics 
2014;32:1185-99. 
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reporting but not the methodological quality of the studies81. From our 
perspective, the low number of full EE based on RCT/c-RCT makes it 
difficult drawing firm conclusions about the cost-effectiveness of PPSs in 
community pharmacy; however it does not preclude from observing a trend 
towards the cost-effectiveness of this technology. 
Due to the important concerns about the validity of pooled values of 
EE of different types of EE, costs and healthcare systems53,62,82, the aim of the 
systematic review was not necessarily to establish a numeric incremental cost-
effectiveness ratio for the PPS compared with the UC. The aim was to 
perform a mapping of the available evidence to ascertain if PPSs have been 
found to be cost-effective in specific countries and health systems. We aimed 
to generate evidence for decision makers to assess the feasibility of PPSs in 
their own health systems. Permutation matrix proposed by Nixon et al63 was 
selected to summarise the ICER results in a qualitative way since the matrix is 
a visual and simple method to communicate complex health economic 
outcomes to non-expert audience and findings can be easily used to make 
decisions on healthcare resource allocation. The main limitation of the matrix 
                                                 
81 Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. 
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and 
elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines 
Good Reporting Practices Task Force. Value in health 2013;16:231-50. 
82 Drummond MF. Comparing cost-effectiveness across countries: the model of acid-related 
disease. Pharmacoeconomics. 1994;5(Suppl.3):60-7. 
Methods and results 
 98 
 
is that it loses important information to interpret the ICER, such as the 
uncertainty and quality of the studies. However in this review quality was 
assessed separately and symbols indicating the quality of each study were 
added in the matrix. Narrative results and tables summarizing the main 
information of individual studies are still needed to understand and interpret 
all the factors that affect the ICERs. In fact, we had several concerns when 
allocating a position in the matrix to the studies performed by Rubio-Valera et 
al71 and Bosmans et al66 due to the high uncertainty. Finally we followed the 
pre-specified criterion of allocating depending on the ICER point estimates 
since we were not able to systematically include the assessment of the 
sensitivity analysis when making this decision.  
Limitations of this systematic review include a potential risk of 
publication bias, since grey literature was not specifically searched. However, 
the grey literature identified in manual searching was assessed for inclusion. 
Secondly, it was not possible to conduct subgroup analyses to investigate the 
impact of the type of PPS, EE, country or time horizon as a result of the 
relatively limited number of included studies. Findings cannot be extrapolated 
to underdeveloped or developing countries since all the included studies were 
carried out in developed countries. Another review with more relaxed 
exclusion criteria should be conducted to retrieve the studies carried out in 
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underdeveloped or developing countries. Finally, we acknowledge that 
including only full EE based on RCT/c-RCT, information given by other 
type of studies was not included. However, the inclusion of studies providing 
only the highest level of evidence was preferred. 
Key recommendations arise from this review for future research. On 
one hand, the use of QALYs is recommended in ICER calculations. Besides 
increasing comparability among studies, QALYs are preference-based final 
outcomes. Additionally, although cost-benefit analyses were not found in this 
systematic review, their use should be considered since the cost-benefit ratio 
could give useful and easily manageable information to decision makers. Most 
of the EE were undertaken from the healthcare system perspective. However 
it would be interesting to complement these analyses with the societal 
perspective to assess the impact of PPSs on direct non-medical and indirect 
costs such as patients’ time, transport or productivity loses. A better 
identification and measurement of costs is needed. Costs to perform the 
intervention should always be included, and costs that potentially can be 
affected as a result of the intervention depending on the perspective chosen 
should also be included. If any important cost could not be measured it 
should be discussed in limitations. Additionally, a higher level of reliability 
and validity could be achieved if the use of health resources could be 
Methods and results 
 100 
 
confirmed through medical records rather than being only self-reported by 
patients. The lack of concordance in hospital admissions when using self-
reported data vs. medical records has been reported45 and systems to ensure 
the appropriate recovery of these events are needed, since a single event has a 
high impact in total costs. Instead of the cost-consequence analysis used in 
some of the studies64,65,70,73, when clinical and/or humanistic outcomes and 
economic data are measured in a RCT/c-RCT, calculations on the 
incremental cost-effectiveness and appropriate sensitivity analyses are strongly 
encouraged since cost-effectiveness data summarized in an incremental ratio 
are easier to manage than disaggregated cost and consequence outcomes. 
Finally, only three studies used modelling techniques to lengthen the 
time horizon of the EEs based on RCT/c-RCT with short follow-up to allow 
capturing all the relevant cost and consequences40,69,77. The difference between 
ICERs for short vs. long-time horizons and sensitivity analyses40,77 suggest 
that the costs associated with the intervention in short term, such as the cost 
of pharmacist training, had disappeared over time and the effectiveness of the 
service would be retained. It seems that if ICERs calculated for short time 
horizon were modelled to longer periods, the PPS would be more cost-
effective. Nevertheless, the question of what is the appropriate time horizon 
for capturing all relevant cost and consequences of PPSs without relying on 
Methods and results 
 101 
 
too many assumptions still needs to be answered. It would probably need to 
be individualised for every EE depending on the type of PPS assessed and the 
length of time needed to see the change of the effect on measured outcomes. 
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1.5 Conclusions 
In conclusion, the current systematic review performs a mapping of the 
studies assessing the cost-effectiveness of PPSs provided to patients attending 
the community pharmacy. Due to the limited comparability, low number of 
studies, few types of PPSs analysed and the uncertainty related to some 
ICERs, the actual evidence should be complemented with other high quality 
studies. From the available evidence it could be concluded that there was a 
general trend towards the cost-effectiveness of PPSs in community pharmacy 
compared to UC. Decision makers are encouraged to consider the feasibility 
of implementing and funding community pharmacist-led professional services 
in their specific health systems. 
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2.1 Introduction 
Drug related problems and negative clinical outcomes related to 
medicines have a significant clinical and economic burden83,84 with the aged 
polypharmacy patients population being at high risk21. A direct positive 
correlation has been found between ageing, polypharmacy and an increased 
risk of DRPs and NCOMs. A recent study reporting the prevalence of DRPs 
in aged patients using eight or more medications, found that 87% of the 
analysed patients had at least one DRP21. Another study found 8.9 DRPs per 
patient with a mean age of 81 years and using 15 medicines22.  
These medication errors use social and health resources and generate 
costs to the healthcare system. Interestingly a high percentage of NCOMs are 
preventable, as evidenced in a Spanish study undertaken in a hospital setting19. 
These researchers estimated costs up to €14.5 million for ED visits caused by 
preventable NCOMs during the 2003 year. Johnson and Bootman85 estimated 
that the cost associated with drug-related morbidity and mortality in 
                                                 
83 Chiatti C, Bustacchini S, Furneri G, Mantovani L, Cristiani M, Misuraca C, et al. The 
economic burden of inappropriate drug prescribing, lack of adherence and compliance, 
adverse drug events in older people: a systematic review. Drug Saf. 2012;35 Suppl 1:73-87. 
84 Beer C, Hyde Z, Almeida OP, Norman P, Hankey GJ, Yeap BB, et al. Quality use of 
medicines and health outcomes among a cohort of community dwelling older men: an 
observational study. Br J Clin Pharmacol. 2011;71(4):592-9. 
85 Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. 
Arch Intern Med. 1995;155(18):1949-56. 
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ambulatory care in the U.S. was $76.6 billion (in 1995 values, only direct 
medical costs).  Other authors24 updated these estimates to the year 2000, 
reporting costs of $177.4 billion. They concluded that given the economic 
and medical burden associated with DRPs, the implementation of strategies 
for preventing drug-related morbidity and mortality are urgently needed.  
An individualized review of patients’ pharmacotherapy has been proven 
to be an effective strategy to avoid preventable NCOMs, reducing the clinical 
and economic burden86. A series of systematic reviews conclude that PPSs 
generally provide positive economic benefits, although there is high variability 
in both clinical outcomes and the subsequent cost-effectiveness 
analysis32,42,43,52. 
The conSIGUE Program was carried out to assess the impact of the 
MRF to aged patients with polypharmacy46. MRF has been shown to be a 
cost-effective strategy through a CUA68. However, policymakers requested 
other economic evidence different to the CUA in the process of considering a 
change in health policy and a payment for the service. 
                                                 
86 Brummel A, Lustig A, Westrich K, Evans MA, Plank GS, Penso J, et al. Best practices: 
improving patient outcomes and costs in an ACO through comprehensive medication 
therapy management. JMCP. 2014;20(12):1152-8. 
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The aim of this paper was to ascertain the economic impact of the 
MRF service provided in community pharmacy to aged polypharmacy 
patients comparing MRF with UC, by undertaking a cost analysis and a cost 
benefit analysis. 
Experimental design and results 
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2.2 Methods 
2.2.1 Study design 
The conSIGUE Program has been described previously in this thesis, 
and sampling and the research methodology was fully described in a report46. 
Briefly, a cluster randomized controlled trial was carried out in 178 
community pharmacies in 4 Spanish provinces with 6 months fieldwork in 
each province. Following a request for participation for all community 
pharmacies within a province those willing to participate were randomly 
allocated into either the IG or CG. Each pharmacy was required to recruit up 
to 10 aged polypharmacy patients, defined as those aged ≥ 65 years and 
taking 5 or more medications for at least 6 months. Neither patients nor 
pharmacists could be blinded due to the characteristics of the intervention.  
A piggyback cost-benefit analysis and a cost analysis were performed 
from the Spanish National Health System (NHS) perspective, with a time 
horizon of 6 months. Additionally, different extrapolations were made to 
estimate the outcomes depending on length of follow-up, number of patients 
receiving the MRF and a payment to pharmacies for delivering the service. 
The alternatives were a MRF service versus the usual care. 
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2.2.2 Medication review with follow-up service and study 
groups 
Pharmacists allocated to MRF group delivered the service according to 
national guidelines31. MRF starts with a patient interview, in which the 
pharmacist collects relevant information about health problems, medicines 
used, clinical and biological parameters, medication use, lifestyle habits, and 
patient concerns about diseases and medications. After performing a 
comprehensive medication review, the pharmacist identifies NCOMs and 
DRPs. An action plan is agreed with the patient and the physician if required. 
Patients included in the CG received UC. The UC in Spanish 
community pharmacy setting consists of dispensing medicines prescribed by 
physicians and minor ailments advice47. During the 6 months of follow-up, 
patients in both study groups attended the pharmacy on a monthly basis. 
Study variables were systematically collected at every patient visit to the 
pharmacy. Neither patients nor pharmacists received any incentives for 
participating in the study. 
Experimental design and results 
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2.2.3 Costs 
The economic evaluation was conducted from the health system 
perspective. The following direct medical costs were included in the analysis: 
medication costs, ED visits costs, hospital admission costs, the cost of 
pharmacists’ time, pharmacists training and the cost of the practice change 
facilitator. Additionally, the investment of the pharmacy was also considered 
to establish the cost of the intervention. Costs are expressed in Euros at 2014 
prices. Prices from previous years were updated using the Spanish consumer 
price index. 
The information about medicines used was obtained from the records 
completed by pharmacists during the monthly visits with patients and 
validated by the practice change facilitators. Retail prices of the medicines 
were used87. All the products registered as medicines in Spain, involving 
prescribed and over the counter medications, were included. 
                                                 
87 BotPLUS web database. Spanish General Council of Official Colleges of Pharmacists. 
Madrid. Available from: https://botplusweb.portalfarma.com/. [Accessed November 15, 
2014]. 
Methods and results 
 111 
 
Patients reported the number of times they had visited the emergency 
department throughout the follow-up. The reference sources for the unit 
costs of ED visits were the tariffs of the regional health services88,89,90. 
Patients were required to report the number of hospital admissions 
during the follow-up. The list of diagnosis related groups (DRGs) was 
requested from the regional health directorates and hospitals. When the 
information reported by patients and the one provided by official sources was 
discordant, the latter was accepted. Costs of DRG were taken from the 
Spanish NHS91. Three specialists in internal medicine independently assessed 
the causes of hospital admission and only those associated with DRPs were 
included in the analysis45. 
The time spent by pharmacists during the provision of MRF was 
obtained from pharmacists´ data collection forms. Missing data were replaced 
                                                 
88 Order of 14 october 2005, which fixes public prices of health services provided by the 
Public Health System of Andalusia, BOJA 210. Available from: 
http://www.juntadeandalucia.es/boja/2005/210/d28.pdf. [Accessed June 12, 2014]. 
89 Tariff book of public prices of the Public Health System of the Basque Country, 2014. 
Osakidetza. Available at: http://www.osakidetza.euskadi.net/r85-
ckproc05/es/contenidos/informacion/libro_tarifas/es_libro/tarifas.html. [Accesed June 4, 
2014]. 
90 Decree 81/2009, 16 June, which fixes the public costs of health services of the Canarian 
Health Service. Available from: http://www.gobiernodecanarias.org/boc/2009/123/boc-
2009-123-002.pdf. [Accessed June 10, 2014]. 
91 Ministry of Health, Social Services and Equalty, Spanish Government. [Weights and costs 
of DRGs. Ministry rule APv27.0.] (2010). Available from: 
http://www.msssi.gob.es/estadEstudios/estadisticas/docs/SNS2011_PESOS_COSTES_AP
27_DEF.pdf. [Accessed July 5, 2014]. 
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with the median value of the variable, in order to avoid an underestimation of 
time costs. Costs for the pharmacist time were calculated multiplying the 
minutes spent during the provision of the service by the wage, depending on 
collective wage agreements in each province and the type of contract of 
employment92. Time spent providing UC was not recorded in conSIGUE 
Program, therefore it was estimated using data previously described in the 
literature93. 
The costs related to the investment of the pharmacy required to 
provide the MRF service during the 6 months of study were obtained through 
a questionnaire completed by pharmacy owners in the MRF group92 
(questionnaire available in reference46). Only the percentage of costs 
attributable to MRF was considered. Investment of pharmacies on fixed and 
variable costs besides the cost of attendance of the pharmacists to the three 
half-day training course were included.  
In order to allocate the proportional part of the cost to every patient, 
the mean cost of investment per pharmacy was divided by the mean number 
of patients included in MRF service per pharmacy (7.9 ± 2.4 patients per 
                                                 
92 Noain A, Garcia-Cardenas V, Gastelurrutia MA, Malet-Larrea A, Martínez-Martínez F, 
Sabater-Hernández D, Benrimoj SI. Cost analysis of a Medication Review with Follow-up 
service provided to elderly patients using polypharmacy. Submitted to Int J Clin Pharm. 
93 Casal-Sánchez C, Losada-Campa MJ. Necessary times for the dispensation of electronic 
prescriptions in Galicia: necessities and processes. Farmacéuticos Comunitarios. 2012;4(2):52-
62. 
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pharmacy). The investment of pharmacies in the UC group was assumed to 
be null. 
Costs of practice change facilitators were met by official pharmacists 
associations in each province. The cost for the practice change facilitator´s 
time was estimated multiplying the working hours by the wage depending on 
the type of contract of employment per province and adding the travel 
expenses to the pharmacies. Practice change facilitators were estimated to 
spend two-thirds of their time with pharmacists in the IG and one-third with 
pharmacists in the CG. The time spent in the CG was allocated to completing 
and validating data collection forms. However since this expenditure was not 
attributable to the provision of the MRF, the cost of practice change 
facilitator in the CG was considered to be null and the proportional part was 
discounted in the IG. 
2.2.4 Benefits 
Patient´s health-related quality of life was measured with the quality-
adjusted life years (QALY). Patients in both study groups completed the EQ-
5D questionnaire at every visit of the patient to the pharmacy94, and utility 
                                                 
94 EuroQol Group. Spanish (Spain) version version of EQ-5D-5L. Rotterdam, 2014. 
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index associated to each health state were estimated using the time trade off 
method95.  
In this cost-benefit analysis, a monetary value obtained through 
empirical research was assigned to the QALY. The assignment of a monetary 
value to the QALY has been the objective of several studies, and the study 
recently published by Robinson et al. collected data from 9 European 
countries, including Spain96. The authors adapted the “chained” approach, 
using first the time trade off and standard gamble methods to elicit utilities 
for health states and then estimating the willingness to pay (WTP) per QALY. 
They suggested that the WTP per QALY ranged from $18,247 to $34,097 
(US dollars, 2013) and we assigned this monetary value to the QALYs 
obtained in our study. 
2.2.5 Sensitivity analysis 
One-way deterministic sensitivity analysis was undertaken in the base 
case of the cost-analysis in order to analyse the uncertainty and to explore the 
impact of varying the input parameters. The alternative values of the 
                                                 
95 Ramos-Goñi JM, Rivero-Arias O. Eq5d: A command to calculate index values for the EQ-
5D quality-of-life instrument. Stata Journal. 2011; 11(1):120-125. 
96 Robinson A, Gyrd-Hansen D, Bacon P, Baker R, Pennington M, Donaldson C, EuroVaQ 
Team. Estimating a WTP-based value of a QALY: the 'chained' approach. Soc Sci Med. 
2013;92:92-104. 
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parameters were their upper and lower variations (for costs related to 
medication, ED visits, pharmacy time and investment of the pharmacy), 
logical values (hospital admissions without cause-effect screening and the 
number of patients that could be attended by each pharmacy in real practice) 
and arbitrary and conservative values in remaining ones (length of follow-up 
and practice change facilitator time). Fourteen scenarios were analysed 
through these alternative values. 
The following assumptions were used to calculate the number of 
patients that could be included in the MRF in real practice: a community 
pharmacy in Spain serves a mean of 2500 patients97; 16% of the population 
are aged patients using polypharmacy98,99, and 60% of these patients would 
accept the provision of service. The MRF service could be delivered to 240 
patients per annum and 120 in 6 months.  
                                                 
97 Statistics Collegiate and Community Pharmacies 2012. Spanish General Council of Official 
Colleges of Pharmacists. Madrid. Available from: 
http://www.portalfarma.com/Profesionales/infoestadistica/Documents/Estadisticas2012.p
df. [Accessed Feb 7, 2015]. 
98 Abellán A, Esparza C. [A profile of the elderly in Spain, 2011. Basic statistical indicators.] 
(Informes Portal Mayores no. 127). Madrid. Available from: 
http://digital.csic.es/bitstream/10261/107721/1/pm-indicadoresbasicos11-1.pdf. [Accessed 
7 Feb 2015]. 
99 Cosby RH, Howard M, Kaczorowski J, Willan AR, Sellors JW. Randomizing patients by 
family practice: sample size estimation, intracluster correlation and data analysis. Fam Pract. 
2003;20(1):77-82. 
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2.2.6 Statistical analysis 
Student´s t-test was used to analyse the differences between IG and 
CG, and Chi Square test or Fisher's exact test to assess the differences in 
frequency distribution. The adjustment of the variables that were significantly 
different at baseline was performed through an analysis of covariance. All 
analyses were conducted using the Statistical Package for the Social Sciences 
(SPSS v. 18.0 for Windows XP, Microsoft, U.S.), Microsoft Excel 2010 and 
STATA version 12 (StataCorp LP, College Station, TX, USA). 
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2.3 Results 
2.3.1 Study groups and patients 
A total of 1474 patients were enrolled in the study. Patient recruitment, 
flow and dropouts are shown in Figure 4. Data on 1403 patients meeting the 
inclusion criteria and allocated into the IG (n=688) or CG (n=715) were 
included in the analysis. Patients were recruited by 178 community 
pharmacies with a mean number of 7.9 (SD 2.4) patients in each pharmacy. 
 
 
 
 
 
 
 
 
 
Figure 4: Participant recruitment, flow and dropouts 
  
1474  
Patients recruited 
Medication Review with 
Follow-up (n=688) 
Usual Care  
(n=715) 
71 Not assessed 
< 65 years old = 28 
< 5 medicines/day = 36 
 < 65 years old and < 5 medicines/day = 7 
42 lost to 
follow up 
Visit 2 = 19 
Visit 3 = 7 
Visit 4 = 1 
Visit 5 = 7 
Visit 6 = 8 
30 lost to 
follow up 
Visit 2 = 13 
Visit 3 = 5  
Visit 4 = 6 
Visit 5 = 2 
Visit 6 = 4 
1331  
6 month follow up completed 
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Table 4 shows the socio-demographic and clinical characteristics of 
patients at baseline and last study visits. Patients in IG used significantly more 
medicines, had more health problems and uncontrolled health problems than 
in CG at baseline (p<0.05).  Every acute or chronic manifested health issues 
were considered health problems, and the level of control was assessed by 
pharmacists using information referred by patients’ and/or clinical and 
biological parameters. At the end of the study the number of uncontrolled 
health problems had decreased in the IG more than 50% (p<0.001), 
becoming similar to the CG. The number of patients with visits to ED or 
being hospitalised decreased in the IG leading to significant differences 
between groups after the 6-month follow-up45. Utility scores were similar 
between groups at baseline; they remained constant in the CG while increased 
in IG, leading to significant differences between groups as well. 
2.3.2 Costs and cost analysis 
Pharmacists spent a median of 350 minutes (interquartile range: 265-
490 minutes) in the provision of the service per patient for all phases of MRF 
during the 6 months study. Time required to provide the UC in Spain through 
the dispensing service with electronic prescription was estimated to be 4.2 
minutes/patient´s visit to the pharmacy93. Taking into account the number of 
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patients lost to follow-up, pharmacists would need 25 minutes/patient to 
provide UC during the 6 months. 
Table 4: Socio-demographic and clinical characteristics of the patients at 
baseline and at 6-month follow-up (mean (SD) unless otherwise reported) 
 IG CG P-value 
Age (years) 75.3 (6.5) 74.9 (6.6) 0.243 
Gender (female); n (%) 409 (60.1) 441 (61.7) 0.535 
Number of medicines used    
   Period 1 7.7 (2.5) 7.4 (2.4) 0.009 
   Period 6 7.5 (2.4) 7.3 (2.4) 0.204 
Health problems    
   Period 1 4.9 (1.8) 4.3 (1.5) <0.001 
   Period 6 4.9 (1.8) 4.3 (1.5) <0.001 
Uncontrolled health problems    
   Period 1 1.5 (1.3) 0.7 (1.0) <0.001 
   Period 6 0.6 (0.9) 0.7 (0.9) 0.217 
Patients in emergency department; n (%)    
   Period 1 193 (28.1) 211 (29.5) 0.556 
   Period 6 90 (13.1) 173 (24.2) <0.001 
Patients hospitalised; n (%)    
   Period 1 89 (13.4) 68 (9.9) 0.044 
   Period 6 38 (6.2) 65 (9.8) 0.018 
Utility scores    
   Period 1 0.715 (0.3) 0.693 (0.3) 0.238 
   Period 6 0.768 (0.3) 0.693 (0.3) <0.001 
   IG: intervention group. CG: comparison group. SD: standard deviation. 
The investment needed by pharmacies to provide MRF service in the 
conSIGUE Program was 210.8 (SD: 32.8)92 and the highest costs were 
associated with pharmacists´ attendance to the training course. 
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Amongst the 83 hospital admissions screened by the expert panel, 42 
(50.6%) were related to medication (IG: 11, CG: 31; p=0.042). 
Table 5: Unit and total costs of study groups (€, 2014) during 6 month follow-up 
Item 
Unit cost (€) 
and reference 
source 
Number Total cost (€) % of total 
IG CG IG CG IG CG 
Medication  
(nº packages) 
Retail 
pricea 
29,353 29,974 425,460 459,157 63.3 62.7 
Emergency department visits (nº visits)     
Andalusia 
Basque Country 
Canary Islands 
58.55b 
149.50c 
216.93d 
30 
41 
47 
59 
58 
173 
1,756 
6,129 
10,195 
3,454 
8,671 
37,528 
2.7 6.7 
Drug related 
hospital 
admissions 
(nº admissions) 
 
Diagnosis 
Related 
Group e 
11 31 64,846.4 215,382 9.6 29.4 
Pharmacy time 
(cost/min) 0.443
 f 240,800 17,426 106,674 7,719 15.8 1.0 
Investment in 
MRF 
(per pharmacy) 
210.8 g 88 - 18,553 - 2.7 - 
Practice change  
facilitator time 
(cost/min) 
1.012 h 37,661 - 38,112 - 5.6  
Total cost 
 
- 
 
- 
 
- 
671,730 731,914 100 100 
aSpanish General Council of Colleges of Pharmacists87; bTariffs of Andalusian health service88; 
cTariffs of Basque Country health service89; dTariffs of Canarian health service90; eTariffs of 
Spanish National Health Service91;  f,g,hOwn data. IG: intervention group. CG: comparison group 
. 
The average costs of a practice change facilitator (wage plus travel 
expenses) was € 1616.6 per month. Taking into account that practice change 
facilitators worked 40h per week, the mean cost per practice change facilitator 
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was €0.169/min. Six practice change facilitators were employed with a total 
cost of €1.012/min.  
Table 5 summarizes the unit and total costs for both groups. The 
highest cost was medication, with more than 60% of the total cost in both 
groups. The second most influential cost component was drug related 
hospital admissions for UC group and pharmacy time for MRF group, being 
the investment of the pharmacy the component having less weight. 
Table 6: Mean costs per patient (€, 2014) during 6 month follow-up 
Item IG CG Mean differencea 
Medication costs; 
mean (SE)b 
615.5 (25.7) 661.3 (25.0) -45.8 
Emergency department 
visits; mean (SD) 
26.3 (81.6) 69.5 (222.6) -43.2 
Hospital admissions; 
meanc 
94.2 301.2 -207.0 
Pharmacy time; 
MRF: median (Q25 – Q75) 
155.1 
(117.4 – 217.1) 
11.1 144 
Investment of pharmacy 
in MRF; mean (SD) 
26.9 (3.8) - 26.9 
Practice change facilitator 
time; mean 
27.7 - 27.7 
Total 945.7 1043.1 -97.4 
aNegative cost difference indicates cost saving related to MRF group bAdjusted by the number of 
used medicines in period 1 (ANCOVA) cMalet-Larrea et al.45. IG: intervention group. CG: 
comparison group. SE: Standard error; SD: standard deviation. 
 
The cost savings per patient of the base case are shown in Table 6. Cost 
differences between groups in medication, ED visits and hospital admissions 
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were statistically significant (p<0.001 for medication and ED visits and 0.018 
for hospital admissions). The difference between total costs in both groups 
showed a cost saving for the NHS of € 97 per patient in 6 months.  
In order to obtain a profit margin of 30%, which is the current margin 
paid to pharmacies for each product supply by the NHS, pharmacies should 
receive €22 per patient-month for providing the MRF92. If health 
administration paid €22 per patient-month, the net saving of the MRF service 
would be € 273 per patient-year.   
However, the saving obtained suggests that the service would be 
efficient even with a higher price than €22 per patient-month. Based on 
annual estimates, the threshold price for the efficiency of the MRF is 
expected to be €45 per patient-month. All the extrapolations are summarised 
in Table 7. 
The sensitivity analysis showed that the MRF saved costs in 13 of 14 
scenarios analysed. The MRF would achieve savings of €398 per patient in the 
scenario where 240 patients were included in the service per pharmacy during 
one year. In this case, if the service was remunerated, savings per patient-year 
would be €326 and each pharmacy would save €78,281 per year. 
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Table 7: Summary of calculations and extrapolations 
Scenario 
Time, unit of analysis 
and key assumptions 
Variables and values Cost-
savings (€) 
a) Base case scenario 
conSIGUE Program 
6 months, patient 
Medication: -45.8 
ED visits: -43.2 
Hospital admissions: -207.0 
Pharmacy time: 144 
Investment of pharmacy: 26.9 
Practice change facilitator: 27.7 
-97 
b) Including fee for 
service  
1 year, patient 
The fee for service 
calculation includes the 
cost of the intervention for 
the pharmacy; 22*12=264 
Medication: -91.7 
ED visits: -86.3 
Hospital admissions: -413.9 
Practice change facilitator: 55.4 
Fee for service: 264 
-273 
c) Fee for service 
threshold analysis 
1 month, fee for service 
Threshold: when cost-
savings=0 
Medication: -91.7 
ED visits: -86.3 
Hospital admissions: -413.9 
Practice change facilitator: 55.4 
= -536.58 / 12 
-45 
d) Including a real 
number of patients 
(n=240) 
1 year, patient 
Intervention cost: share 
among 240 patients and 
extend follow-up visits 
time 
Medication: -91.7 
ED visits: -86.3 
Hospital admissions: -413.9 
Pharmacy time: 190.9 
Investment of pharmacy: 0.9 
Practice change facilitator: 1.8 
-398 
e) Including a real 
number of patients 
(n=240) and fee for 
service 
1 year, patient 
Former scenario with fee 
for service including cost 
of the intervention for the 
pharmacy(22*12=264) 
Medication: -91.7 
ED visits: -86.3 
Hospital admissions: -413.9 
Practice change facilitator: 1.8 
Fee for service: 264 
-326 
f) Including a real 
number of patients 
(n=240) and fee for 
service 
1 year, pharmacy 
Former scenario, per 
pharmacy with 240 
patients 
Medication: -91.7 
ED visits: -86.3 
Hospital admissions: -413.9 
Practice change facilitator: 1.8 
Fee for service: 264 
-78,281 
aNegative cost difference indicates cost saving related to MRF group. ED visits: 
emergency department visits. 
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2.3.3 Cost-benefit analysis 
The cost-benefit analysis considered the health benefits obtained by the 
provision of MRF in addition to the costs savings (Figure 5). The QALY 
obtained were 0.3721 (0.12) in the IG and 0.3488 (0.15) in the CG (p=0.002). 
Two scenarios were set up using the base case of the cost analysis and the 
upper and lower limit of the estimated range for the monetary value of 
QALY in the European study96. The cost-benefit ratio indicated that MRF 
benefits were from 3.3 to 6.2 times higher than costs. When benefits in health 
were added, every case considered in the sensitivity analysis provided positive 
results for the MRF. 
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Figure 5: Cost benefit analysis (€, 2014) of the medication review with follow-
up per patient in 6 months 
The scenarios are given by the monetary value of QALY reported in the study by 
Robinson et al.
96
. IG: intervention group. CG: comparison group. 
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2.4 Discussion 
The results of the present study show that MRF delivered in a 
community pharmacy setting targeted to aged polypharmacy patients has 
positive net benefits (between €420 and €700 per patient) and it saved €97 per 
patient in 6 months. For every €1 invested in MRF, the service returned a 
benefit from €3.3 to €6.2. 
The analysis showed that if MRF was implemented in clinical practice, 
higher saving could be achieved. There were decreasing marginal costs of the 
intervention with the length of the follow-up and with the number of patients 
in the programme. Thus, the inclusion and maintenance of a higher number 
of patients during a longer period of time would generate more savings to the 
healthcare system. However, the sustainability of the service depends on its 
payment. Pharmacists would need a fee for service to deliver MRF to a higher 
number of patients and during a longer follow-up. Even if the health system 
remunerated pharmacists with €22 per patient-month, savings per patient-year 
would amount to €326. 
Diverse results have been found when assessing the cost-effectiveness 
of PPSs67,77. Our results support the evidence suggesting that pharmacist 
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interventions might be cost-effective and cost-saving100,101,102. For example, a 
recent study carried out in a hospital setting102 found a cost-benefit ratio of 
€1:8.64 for pharmacist interventions. Another study aimed at improving the 
quality of prescribing and the adherence to treatment by community 
pharmacists in patients with hypertension showed that benefits obtained were 
ten times higher than costs101. In the Asheville project a similar service to 
MRF was delivered by community and hospital pharmacists over 6 years in 
patients with different chronic conditions such as asthma103, hypertension 
and/or dyslipidaemia104. Similar results to the ones found in our study were 
achieved. The pharmacy service provided allowed not only clinical 
improvements (supported by a decrease in ED visits and hospital admissions) 
but also cost savings (direct cost savings averaged $725 per patient-year). 
Findings of Asheville Project and conSIGUE Program are highly comparable 
due to the fact that the service provided was very similar, including the 
follow-up using scheduled consultations. 
                                                 
100 Benrimoj SI, Langford JH, Berry G, Collins D, Lauchlan R, Stewart K, et al. Economic 
impact of increased clinical intervention rates in community pharmacy. A randomised trial of 
the effect of education and a professional allowance. Pharmacoeconomics. 2000;18(5):459-68. 
101 Cote I, Gregoire JP, Moisan J, Chabot I, Lacroix G. A pharmacy-based health promotion 
programme in hypertension: cost-benefit analysis. Pharmacoeconomics. 2003;21(6):415-28. 
102 Gallagher J, Byrne S, Woods N, Lynch D, McCarthy S. Cost-outcome description of 
clinical pharmacist interventions in a university teaching hospital. BMC Health Serv Res. 
2014;14:177. 
103 Bunting BA, Cranor CW. The Asheville Project: long-term clinical, humanistic, and 
economic outcomes of a community-based medication therapy management program for 
asthma. J Am Pharm Assoc. 2006;46(2):133-47. 
104 Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic 
outcomes of a community-based long-term medication therapy management program for 
hypertension and dyslipidemia. J Am Pharm Assoc. 2008;48(1):23-31. 
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MRF is a well-defined service, which includes a comprehensive and 
systematic medication review and a follow-up commitment. The provision of 
MRF requires a considerable investment of time, clinical knowledge and 
effort, since pharmacists are responsible for not only the process of the use of 
medicines, but also patients´ health outcomes. Additionally, pharmacists in 
conSIGUE Program were supported by a practice change facilitator. 
Consequently, the MRF provided in conSIGUE Program achieved clinical 
results not found with other pharmacy services34,105. 
In fact, other studies showed even greater cost-benefit ratios such us 
those included in a series of systematic reviews 1:34.61, 1:17.0, 1:25.95, 
1:75.8432,42,43,52. However these extreme values should be considered 
exceptional cases. The study design, included costs, type of pharmacy service 
and patients´ characteristics has an undeniable impact on the results. For 
instance, the study reporting a cost-benefit of 1:75.84 assessed the impact of a 
pharmacokinetic service in hospitalised patients receiving aminoglycosides, a 
specific service in ill patients treated with narrow therapeutic range medicines. 
These patients were at a very high risk of complications, so there was every 
chance of avoiding higher clinical and economic burden than services like 
MRF, provided to ambulatory patients with chronic comorbidities.  
                                                 
105 Beaucage K, Lachance-Demers H, Ngo TT, Vachon C, Lamarre D, Guevin JF, et al. 
Telephone follow-up of patients receiving antibiotic prescriptions from community 
pharmacies. Am J Health Syst Pharm. 2006;63(6):557-63. 
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Nevertheless, the median values of cost-benefit ratios of the studies included 
in the reviews are similar to our cost-benefit ratio, endorsing our findings 
($1:4.1, $1:4.68 and $1:4.8132). 
The main purpose of EE is for policymakers to make decisions. If 
policymakers and their political advisors do not have strong technical 
knowledge in health economics, the presentation of clear EE to inform the 
process of decision making is required. In the consultations with Spanish 
policymakers, it was evident that the “cost per QALY” concept generated in 
the previous economic evaluation of the conSIGUE Program68 was difficult 
to understand. In this analysis we translated this abstract concept to a more 
easily interpretable cost-benefit ratio. Furthermore, in this analysis we 
included more accurate costs and estimations of the economic impact that 
could be expected when implementing the MRF in the real practice. 
The monetary value of health gain used in this analysis was obtained 
through empirical research rather than cost-effectiveness thresholds based on 
literature reviews106 with lack of explicit scientific evidence107. The assignment 
of a monetary value to the QALY has been the objective of several 
                                                 
106 Sacristan JA, Oliva J, Del Llano J, Prieto L, Pinto JL. [What is an efficient health 
technology in Spain?]. Gac Sanit. 2002;16(4):334-43. 
107 Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on 
willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost 
effectiveness? Health econ. 2010;19(4):422-37. 
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studies108,109,110. However these studies performed their estimations with a high 
level of variability. One of the most recent studies is the one developed by 
Robinson et al.96 whose estimations have been used in the present study, and 
where the monetary value of QALY was estimated by the “chained” 
approach through data from 9 European countries, including Spain. 
Robinson et al. suggested that the WTP per QALY ranged from $18,247 to 
$34,097 (US dollars, 2013). In a previous study King et al.109 found that the 
mean WTP per QALY ranged from $12,500 to $32,200 (2003 $US). These 
data obtained by contingent valuation are lower than the currently used cost-
effectiveness thresholds, so the willingness of society to pay might have been 
overestimated when accepting cost-effectiveness thresholds. Alternatively, it 
is known that the WTP per QALY is higher for worse health status than for 
better ones111. In our study, patients´ health status was better than in 
Robinson’s study and therefore, the cost-benefit ratio obtained using the 
lower limit of the monetary value of QALY (3.3:1) would be more likely to 
happen than 6.2:1. 
                                                 
108 Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a 
quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-42. 
109 King JT Jr, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life 
year: implications for societal health care resource allocation. Med Decis Making. 
2005;25(6):667-77. 
110 Pinto-Prades JL, Loomes G, Brey R. Trying to estimate a monetary value for the QALY. J 
Health Econ. 2009;28(3):553-62. 
111 Shiroiwa T, Igarashi A, Fukuda T, Ikeda S. WTP for a QALY and health states: More 
money for severer health states? Cost Eff Resour Alloc. 2013;11:22. 
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The main limitation of the study could be that some direct medical 
costs such as visits to the physician, visits to specialist doctors and laboratory 
costs were not assessed in the conSIGUE Program, and therefore could not 
be included in this analysis. The number of visits to the physician is the 
indicator most likely to be affected by MRF service provision. However, 
several studies assessing similar services to MRF concluded that there are not 
significant differences in number of visits64, cost 112 or both113 of physician 
visits between IG and CG. 
                                                 
112 Cowper PA, Weinberger M, Hanlon JT, Landsman PB, Samsa GP, Uttech KM, et al. The 
cost-effectiveness of a clinical pharmacist intervention among elderly outpatients. 
Pharmacotherapy. 1998;18(2):327-32. 
113 Touchette DR, Masica AL, Dolor RJ, Schumock GT, Choi YK, Kim Y, et al. Safety-
focused medication therapy management: a randomized controlled trial. J Am Pharm Assoc 
(2003). 2012;52(5):603-12. 
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2.5 Conclusions 
In the context of the economic pressure on the healthcare system, the 
identification and implementation of alternatives to increase the efficiency of 
health services and ensure the sustainability of the health system are required. 
Our study showed that MRF provided by community pharmacists, targeted to 
aged polypharmacy patients and compared to the UC, avoids substantial costs 
to the NHS besides providing health benefits to patients. Investment in the 
implementation of this service would represent an efficient use of healthcare 
resources, and a payment from the NHS to pharmacies for delivering MRF 
should be considered.  
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3.1 Introduction 
Morbidity associated with the use of medicines represents an important 
clinical burden15,16,18,20,114,115. A systematic review found that adverse events 
during hospital admission affect almost one in every 10 patients, with 50% of 
them being preventable16. Between 0.1% and 54% of hospital admissions are 
medication-related with 20% being most common. Of these admissions 50% 
are preventable and most of them involve the elderly population15,20,115,116. 
The economic burden arising from healthcare resource consumption 
associated with drug related morbidity and mortality in ambulatory care in the 
US was estimated to be $177.4 billion (2000 year data)24. In the Netherlands 
potentially preventable medication-related hospital admissions cost more than 
€94 million in 2006 or €5461 for each hospital admission26.  
An ageing population and the use of polypharmacy are risk factors for 
suffering not only DRPs18 but also medication-related hospital admissions20. 
Therefore, aged patients using polypharmacy are bound to benefit from 
healthcare interventions aimed at resolving DRPs. 
                                                 
114 Lewis PJ, Dornan T, Taylor D, Tully MP, Wass V, Ashcroft DM. Prevalence, incidence 
and nature of prescribing errors in hospital inpatients: a systematic review. Drug Saf. 
2009;32(5):379-89. 
115 McLachlan CY, Yi M, Ling A, Jardine DL. Adverse drug events are a major cause of acute 
medical admission. Intern Med J. 2014;44(7):633-8. 
116 Leendertse AJ, Visser D, Egberts AC, Bemt PM. The relationship between study 
characteristics and the prevalence of medication-related hospitalizations: a literature review 
and novel analysis. Drug Saf. 2010;33(3):233–44. 
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Professional or cognitive pharmacy services are ‘an action or set of 
actions undertaken in or organized by a pharmacy, delivered by a pharmacist 
or other health practitioner, who applies their specialized health knowledge 
personally or via an intermediary, with a patient/client, population or other 
health professional, to optimize the process of care, with the aim to improve 
health outcomes and the value of healthcare’117. PPSs are an effective strategy 
to avoid and resolve drug related problems as well as negative clinical 
outcomes related to medicines. However, their effectiveness on reducing 
hospital admissions has not been clearly established34. 
A nationwide research project called ‘conSIGUE Program’ was 
undertaken in Spain with the aim of assessing the economic, clinical and 
humanistic impact of a MRF service, provided in community pharmacies to 
aged polypharmacy patients46. The conSIGUE Program obtained promising 
results in terms of hospital admission rates, as shown in the non-peer 
reviewed report published by the Spanish General Council of Official 
Colleges of Pharmacists46. However, a more in-depth analysis was needed to 
analyse the cause and effect relationship between medication use and 
hospitalisations. The aims of the present study were to assess the impact of 
                                                 
117 Moullin JC, Sabater-Hernandez D, Fernandez-Llimos F, Benrimoj SI. Defining 
professional pharmacy services in community pharmacy. Res Social Adm Pharm. 
2013;9(6):989-95. 
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community pharmacy-led MRF provided to aged polypharmacy patients on 
the number of medication related hospital admissions and estimate the effect 
on hospital costs. 
Experimental design and results 
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3.2 Methods 
The main study was the conSIGUE Program, the previously described 
cluster randomized controlled trial aimed at assessing the clinical, economic 
and humanistic impact of the MRF performed in community pharmacy on 
aged polypharmacy patients. The aim of the retrospective sub-analysis 
reported in this manuscript was to analyse the impact of the MRF on hospital 
admissions. Therefore, hospital admissions occurring during the main study 
were retrieved and an expert panel was convened in order to separate those 
hospital admissions related to medicines from hospital admissions not related 
to medicines (see Figure 6). 
3.2.1 Study design 
This retrospective sub-analysis consisted of an expert panel that 
analysed the clinical cases of patients hospitalised during the 6 month follow-
up period of the previously described cluster randomized controlled trial, in 
order to identify medication-related hospital admissions. 
Methods and results 
 139 
 
3.2.2 Study population: clinical cases of hospital admissions 
Clinical cases of those patients hospitalised during the 6 months of 
follow-up of the conSIGUE Program were retrieved. Patient’s self-reported 
information on hospitalisations was verified with the official records of the 
Spanish public health network. The list of DRGs was requested from the 
regional health directorates and public hospitals of the provinces participating 
in the main study. When the information reported by the patient and the 
information provided by regional health directorates or hospitals was 
discordant, the latter was accepted. 
3.2.3 Expert panel 
The expert panel consisted of three internal medicine specialists of the 
Donostia Hospital who had extensive professional experience. Internal 
medicine was considered to be a suitable expertise in the field since it covers 
the diagnosis and treatment of a wide array of diseases, including chronic 
conditions and patients with multi-morbidity. 
The expert panel was informed of the following concepts in a face to 
face meeting: the conceptual and methodological basis of the conSIGUE 
Program, the MRF service, the aim and methodology of this sub-analysis and 
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patient clinical cases. Furthermore, the concept of DRP was clarified and 
experts were provided with the list of DRPs contained in the national 
guidelines31 in order to avoid misconceptions between DRPs and another 
terms like adverse drug reactions. 
The experts were provided with the following information about each 
clinical case: age, gender, health problems, level of control of the health 
problems, daily dose and frequency of the medicines used and the description 
of the DRG. Experts were blinded to the patient group allocation. Records 
were provided in paper and electronic format. 
Initially a pilot study was undertaken to familiarize experts with the 
rating process. Data of five patients of the main study were slightly modified 
in order to maintain the relevant characteristics and avoid the double 
assessment of these cases. All the experts rated the five cases independently, 
and sent the feedback to the research group. 
In the sub-analysis all hospital admission cases were assessed 
independently by each expert. The question posed to the experts was ‘Do you 
think that in this case the hospital admission can be associated with a DRP?’ 
The possible answers were ‘yes’ or ‘no’. Each hospital admission was 
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considered to be associated with a DRP when at least two out of the three 
experts stated so. 
The experts were requested to answer individually for each case and the 
degree of agreement between them was later established. The inter-rater 
reliability (IRR) was measured using Cohen’s kappa for every two raters118 and 
the general agreement was assessed using the Fleiss kappa for multiple 
raters119. 
3.2.4 Outcome measures 
Medication-related hospital admission was the primary outcome of this 
sub-analysis. Hospital admissions were recorded in patients’ visits to the 
pharmacies during the conSIGUE Program and the medication related ones 
were identified through the expert panel after the fieldwork. Kappa values 
ranging from 0.61 to 1 were considered as an acceptable IRR to measure the 
agreement among experts. 
                                                 
118 Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960; 
20(1):37-46. 
119 Fleiss JL. Statistical methods for rates and proportions. New York: John Wiley & Sons, 
1973. 
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The cost of hospital admissions estimated by DRG was a secondary 
outcome and the DRGs were recorded after the fieldwork. Demographic 
variables were recorded at baseline. 
3.2.5 Hospital costs 
DRGs of each hospital admission occurring during the 6 months of the 
main study were gathered from regional health directorates and public 
hospitals. DRGs are the system used in several countries for hospital 
reimbursement and in-hospital budgeting management120. For each hospital 
admission the description of the clinical problem led to the identification of 
the DRG and its designated costs by the Spanish government91. Costs were 
expressed in euros and updated at 2014 prices using the Spanish consumer 
price index. 
3.2.6 Statistical analysis 
Categorical variables were expressed as frequencies and percentages and 
quantitative variables as means and SDs. Student’s t-test was used to analyse 
the differences between the IG and CG and chi square test or Fisher’s exact 
                                                 
120 Vogl M. Assessing DRG cost accounting with respect to resource allocation and tariff 
calculation: the case of Germany. Health Econ Rev. 2012;2:15. 
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test was used to assess the differences in frequency distribution. The risk of 
hospitalisation was calculated through a multivariate logistic regression model 
using the SAS GLIMMIX procedure. This analysis included a random 
intercept for pharmacy-nested within group to account for clustering of 
patients within pharmacies and was adjusted by covariates that could affect 
hospital admissions (age, gender and number of health problems). 
Differences between groups in hospital costs were analysed by hospital 
admission and by patient, and the latter ones adjusted by ANCOVA for the 
number of health problems. Statistical significance was set at P < 0.05. 
Analyses were conducted using SPSS (Statistical Package for the Social 
Sciences v. 18.0 for Windows XP, Microsoft, USA), Epidat (Epidat v. 3.1, 
Galician Health Council and Pan American Health Organization) and SAS 9.4 
(Statistical Analysis Software; SAS Institute, Cary, NC, USA). 
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3.3 Results 
A total of 1403 patients (IG, n = 688; CG, n = 715) were included in 
the main study from 178 pharmacies, with a mean of 7.9 (SD 2.4) patients per 
pharmacy. These patients reported 115 hospital admissions, 83 of them were 
verifiable with official records and their DRGs were retrieved (Figure 6). 
These 83 hospitalisations were distributed over 50 pharmacies. Baseline 
characteristics of hospitalised patients are shown in Table 8. None of the 
patients died during the 6 month follow-up.  
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Figure 6: Pharmacy, patient and hospital admission flow diagram in the main 
cluster randomized controlled trial and in the expert panel sub-analysis 
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According to the expert panel 42 (50.6%) of the hospital admissions 
were medication-related, with a kappa of 0.65 (95% CI 0.52, 0.78; p<0.01). 
Significant differences for medication-related hospital admissions were 
identified between study groups (p=0.042); 31 (73.8%) of the medication-
related hospital admissions occurred in patients in the CG and 11 (26.2%) in 
the IG. 
Table 8: Baseline characteristics of hospitalised patients 
 IG CG P value 
Age (years, mean (SD)) 76.07 (6.62) 74.17 (6.07) 0.240 
Gender (female); n (%) 17 (60.71) 14 (40.00) 0.102 
Partner status (with partner); n (%)* 8 (28.60) 20 (57.10) 0.053 
Education; n (%)**    
   No formal education 6 (21.40) 5 (14.30) 
0.712 
   Completed primary education 8 (28.60) 14 (40.00) 
   Completed secondary education 4 (14.3) 7 (20.00) 
   Completed university education 2 (7.10) 1 (2.9) 
Number of medicines used (mean (SD)) 8.32 (2.40) 7.74 (3.42) 0.450 
Number of health problems (mean (SD)) 6.57 (2.20) 5.23 (1.91) 0.012 
IG: intervention group (n=28); CG: comparison group (n=35).*Missing values: IG =5; 
CG=2. **Missing values: IG=8; CG=8. 
The probability of being hospitalised was significantly higher in the CG 
compared with the IG. The unadjusted model showed an odds ratio (OR) of 
2.7 (95% CI 1.1, 6.7; p=0.036). When adjusting for other covariates (age, 
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gender and number of health problems), the OR increased to 3.7 (95% CI 
1.2, 11.3; p=0.021) (Table 9). The cluster effect was non-existent (intracluster 
correlation coefficient (ICC)=0). 
Table 9: Multivariate logistic regression analysis to assess the effect of 
medication review with follow-up on medication-related hospital admissions 
 Adjusted OR 95% CI P value 
Group (IG  CG) 3.747 1.241-11.319 0.021 
    Age 1.004 0.933-1.080 0.915 
    Gender 0.762 0.290-2.006 0.571 
    Number of health problems 1.180 0.900-1.548 0.222 
IG: intervention group; CG: comparison group; OR: odds ratio; CI: Confidence Interval.  
Raw OR (simple logistic regression analysis): 2.7 (95%CI: 1.1-6.7; p=0.036).  
 
Table 10 shows the level of agreement between the three experts in 
regards to whether hospital admissions could be associated with a DRP or 
not. The multi-rater kappa revealed a substantial agreement degree (kappa = 
0.646; 95% CI 0.52, 0.78, p<0.01)121. 
                                                 
121 Landis JR, Koch GG. The measurement of observer agreement for categorical data. 
Biometrics.1977;33(1):159–74. 
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Table 10: Inter-rater reliability between each pair of rater and overall agreement 
by answering whether hospital admission could be associated with drug related 
problems or not 
Raters Agreement (%) Kappa statistic 95%CI 
Rater 1 vs. Rater 2 83.1 0.667 a 0.51-0.82 
Rater 1 vs. Rater 3 81.9 0.639 a 0.48-0.80 
Rater 2 vs. Rater 3 81.9 0.637 a 0.47-0.80 
Rater 1 vs. Rater 2 vs. Rater 3 73.5 0.646 b 0.52-0.78 
CI=confidence interval. aCohen´s kappa; bFleiss´ kappa. Kappa <0.0 Poor agreement, 
kappa 0.0-0.20 Slight agreement, kappa 0.21-0.40 Fair agreement, kappa 0.41-0.60 
Moderate agreement, kappa 0.61-0.80 Substantial agreement, 0.81-1.0 Almost perfect 
agreement
121
. 
 
The total cost of the hospital admissions (n=83) was found to be 
€516,365. Medication-related hospital admissions (n=42) amounted to 
€280,229 (IG: €64,846; CG: €215,383) and the mean cost per medication-
related hospital admission was €6,672 (SD 5,298) [IG: €5,895 (SD 4,496); CG: 
€6,948 (SD 5,597), p=0.578]. When the costs per group of the medication-
related hospital admissions were divided by the number of patients per group 
in the main study (IG: 688; CG: 715), medication-related hospital admission 
cost per patient receiving MRF was significantly lower than patients receiving 
UC [IG: €94 (SD 917); CG: €301 (SD 2,102); 95% CI 35.9, 378.0; p=0.018]. 
When adjusted by number of health problems similar results were found [IG: 
99 (SE 62), CG: 296 (SE 61); p=0.026]. 
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3.4 Discussion 
More than half of the hospitalisations (42 out of 83) of this sub-analysis 
were medication-related. MRF seems to be an effective strategy to address 
medication-related hospital admissions, since the probability of being 
hospitalised in our study sample was 3.7 times higher in the CG compared 
with the IG (p<0.05). Medication-related hospital costs were significantly 
lower in patients receiving MRF. 
Several PPSs impacted positively on process indicators associated with 
the optimization of the patient’s medication management34. However, the 
impact of these services on outcome indicators remains unclear, as reported 
in a systematic review of systematic reviews published in 201334. This view 
has been endorsed in a number of subsequent systematic reviews and meta-
analyses, in which the evidence of the impact of PPSs on hospital admissions 
is defined as conflicting, insufficient, uncertain or even null122,123,124,36,125,37,126. 
                                                 
122 Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity 
and mortality. Cochrane Database Syst Rev. 2013;2:CD008986. 
123 Hatah E, Braund R, Tordoff J, Duffull SB. A systematic review and meta-analysis of 
pharmacist-led fee-for-services medication review. Br J Clin Pharmacol. 2014;77(1):102–15. 
124 Hohl CM, Wickham ME, Sobolev B, Perry JJ, Sivilotti ML, Garrison S, et al. The effect of 
early in-hospital medication review on health outcomes: a systematic review. Br J Clin 
Pharmacol. 2015;80(1):51–61. 
125 Rotta I, Salgado TM, Silva ML, Correr CJ, Fernandez-Llimos F. Effectiveness of clinical 
pharmacy services: an overview of systematic reviews (2000-2010). Int J Clin Pharm. 
2015;37(5):687-97. 
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However, a large number of studies included in those reviews did not evaluate 
the association of hospital admissions with medicines. This fact may have 
biased the results obtained, since not all hospitalisations may have been 
associated with medications and therefore may not have been avoided 
through the provision of any PPS. 
Additionally, different types of PPSs are compared. However, every 
service differs in its methodology, complexity, collaboration with other 
healthcare providers and level of responsibility assumed by the pharmacist33. 
Therefore it is logical that they are bound to achieve different outcomes. For 
example, the review carried out by Hatah et al.123 performed a subgroup 
analysis showing that a medication review service had significant impact on 
reducing hospitalisations (OR: 0.46; 95% CI 0.26, 0.83), whereas interventions 
focused on adherence did not demonstrate the same trend (OR: 0.88; 95% CI 
0.59, 1.32). Even the same type of PPS may have different characteristics, 
rates of fidelity and implementation. Zermansky et al.127 assessed a pharmacist-
led medication review similar to this MRF. However, the practice change 
facilitator of this study could have increased pharmacists’ fidelity to the 
                                                                                                                          
126 Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, et al. 
Medication therapy management interventions in outpatient settings: a systematic review and 
meta-analysis. JAMA Intern Med. 2015;175(1):76–87. 
127 Zermansky AG, Petty DR, Raynor DK, Freemantle N, Vail A, Lowe CJ. Randomised 
controlled trial of clinical medication review by a pharmacist of elderly patients receiving 
repeat prescriptions in general practice. BMJ. 2001;323:1340–3. 
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methodology and adherence to the guidelines of the MRF leading to the 
achievement of different outcomes. The case study published by Ocampo et 
al.128 in which the service provided was exactly the same as in our study also 
found significant differences in hospital admissions. 
The assessment of patients with different baseline characteristics can 
also be a confounder when analysing the association between the provision of 
PPSs and hospitalisation rates. For example, the meta-analysis carried out by 
Viswanathan et al.126 suggests that the evidence of the impact of medication 
therapy management (MTM) on the outcomes of morbidity and mortality is 
insufficient. Nevertheless, they undertook a sub-analysis on a sample of 
patients suffering from diabetes mellitus or heart failure and it showed that 
MTM decreased the risk of being hospitalised and therefore hospitalisation 
costs. Interestingly, we observed that the baseline number of health problems 
and medicines used by patients in the sub-analysis was much higher than in 
the whole sample of the main study46. It could be said that a MRF service 
might reduce hospitalisations in a more complex type of patient, with specific 
chronic illnesses or treatments. In the future, it would be interesting to 
identify the group of patients who could benefit the most from the MRF. 
                                                 
128 Ocampo CC, Garcia-Cardenas V, Martinez-Martinez F, Benrimoj SI, Amariles P, 
Gastelurrutia MA. Implementation of medication review with follow-up in a Spanish 
community pharmacy and its achieved outcomes. Int J Clin Pharm. 2015;37(5):931-40. 
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In this study, total costs of all the medication-related hospitalisations 
amounted to €280,229 and the cost of a medication-related hospital 
admission was €6,672. Another recent study from the Netherlands estimated 
this cost as €5,46126 indicating some consistency across studies. The mean 
cost per hospital admission was similar in both study groups [IG: €5,895 (SD 
4,496), CG: €6,948 (SD 5,597); p=0.578]. However, when distributing 
medication-related hospitalisation costs among all the patients who had been 
allocated to receive the MRF or UC, costs were significantly lower in patients 
receiving MRF [IG: €94 (SD 917), CG: €301 (SD 2,102); p=0.018]. It can be 
concluded that the MRF avoids costs to the NHS by means of reducing the 
number of hospital admissions rather than reducing the cost per 
hospitalisation. Several economic evaluations of PPSs provided in community 
pharmacy do not include the cost of hospital admissions66,129,130. It could be 
due to the difficulty of accessing these data from the community pharmacy. 
However, the measurement of this variable is encouraged as it could lead to 
the cost-effectiveness of the service. 
                                                 
129 Bond C, Matheson C, Williams S, Williams P, Donnan P. Repeat prescribing: a role for 
community pharmacists in controlling and monitoring repeat prescriptions. Br J Gen Pract. 
2000;50(453):271-5. 
130 Munroe WP, Kunz K, Dalmady-Israel C, Potter L, Schonfeld WH. Economic evaluation 
of pharmacist involvement in disease management in a community pharmacy setting. Clin 
Ther. 1997;19(1):113-23. 
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In the hospitalisation screening, the experts’ independency and 
blindness to the study group were essential to assure the quality of the results 
and minimize possible bias. IRR (kappa = 0.646; 95% CI 0.52, 0.78) reached 
the ‘substantial agreement’ level in the scale proposed by Landis & Koch121. It 
is highly likely that a higher IRR could have been reached if full diagnosis had 
been available for the experts, instead of just DRG description. However, this 
kappa value can be considered acceptable. For instance, the STOPP/START 
criteria, which have been widely accepted and implemented in real practice, 
reached the same level of agreement131. 
A large number of studies reporting the prevalence of medication-
related hospitalisations have been published, although hospitalisation rates 
vary widely. A recently published literature review which sifted through 95 
studies, found that they ranged from 0.1% to 54%116. However, percentages 
around 5.3%15 and 19.4%132 are more frequent. The percentage of 
medication-related hospitalisations in this sub-analysis was high (50.6%, n = 
42) since this study combined several criteria identified as reporting higher 
rates of hospitalisations116: aged patients, consideration of adverse drug events 
instead of adverse drug reactions, inclusion of all hospital admissions rather 
                                                 
131 Gallagher P, Ryan C, Byrne S, Kennedy J, O’Mahony D. STOPP (Screening Tool of Older 
Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). 
Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83. 
132 Perez C, Bermejo T, Delgado E, Carretero E. Adverse drug reactions which provoke 
hospital admission. Farm Hosp. 2011;35(5):236-43. 
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than only acute ones and screening of the hospital admissions through a 
medical chart. Additionally, polypharmacy could be another factor leading to 
more medication related-hospital admissions. 
The small number of hospital admissions may be the main limitation of 
this study. Due to the low frequency of the final outcome, this is a common 
limitation in studies analysing hospitalised patients after receiving a 
pharmacist-led intervention133 and results must be interpreted with caution. 
However, the appropriate sample size could be almost unreachable as was the 
case in a previous study134. Even with few medication-related hospitalisations 
we found significant differences in both number and costs of admissions 
between groups, although confidence intervals were wide. 
There was a lack of concordance between some of the hospital 
admissions self-reported by patients and those recovered from health regional 
directorates and official hospital registrations. Twenty-five of the self-
reported hospital admissions in the CG and seven in the IG were 
unverifiable. Causes of this discordance could include an error in patients’ 
perception, hospital admissions in private hospitals or in different provinces 
                                                 
133 Krska J, Cromarty JA, Arris F, Jamieson D, Hansford D, Duffus PR, et al. Pharmacist-led 
medication review in patients over 65: a randomized, controlled trial in primary care. Age 
Ageing. 2001;30(3):205–11. 
134 Leendertse AJ, Koning GH, Goudswaard AN, Belitser SV, Verhoef M, Gier HJ, et al. 
Preventing hospital admissions by reviewing medication (PHARM) in primary care: an open 
controlled study in an elderly population. J Clin Pharm Ther. 2013;38(5):379-87. 
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from the ones where the study was undertaken. We verified patients’ self-
reported data with official sources, but other systems are needed in future 
studies to ensure the recovery of a greater number of hospital admissions. 
Furthermore, the retrospective design of the study limited the information 
available and it prevented us from comprehensively assessing the 
preventability of the medication-related hospital admissions20 and from 
considering other possible reasons for non-admission to hospital, such us 
admission to care homes. 
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3.5 Conclusions 
Medicines are the most widely used technology to resolve and control 
health problems and they consume a substantial part of the healthcare budget. 
However, this study endorses that patients are suffering a high number of 
hospital admissions due to the ineffective and unsafe use of medicines. Policy 
decision makers should consider the implementation of strategies proven to 
avoid such events in order to optimize population health as well as healthcare 
resource allocation. A MRF service provided by community pharmacists 
might be an effective strategy to balance the assurance of the benefit from 
medications and the avoidance of medication-related hospitalisations in older 
people using polypharmacy. This study provided novel evidence on the 
positive impact of a MRF service on hospital admissions, increasing the well-
being of the elderly and enhancing the allocation of healthcare resources. 
3.6 Reference 
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This thesis has provided evidence on health and economic outcomes of 
professional pharmacy services, and specifically for MRF, in the community 
pharmacy setting. The MRF is a dominant alternative improving patients´ 
health while saving costs to the health system, especially due to its positive 
effect on hospital admissions.  
The cost-effectiveness results of the systematic review showed that 
PPSs can improve patients’ health with low financial investment, and/or even 
saving costs to the healthcare system. Decision makers should consider 
funding services that improve populations’ health outcomes in a cost-
effective way to ensure their sustainability. Several services are being 
remunerated in some countries135. Funding of PPSs across countries could 
facilitate community pharmacy to successfully make the transition started 
some decades ago from product oriented to patient oriented practice136. 
Most of the economic evaluations (7 out of 13) found that PPSs were 
more effective and more costly than the UC, which is the most frequent 
outcome when assessing new healthcare technologies. However, taking into 
                                                 
135 Houle SK, Grindrod KA, Chatterley T, Tsuyuki RT. Paying pharmacists for patient care: 
A systematic review of remunerated pharmacy clinical care services. Can Pharm J (Ott). 
2014;147(4):209-32. 
136 van Mil JWF, Schulz M, Tromp TF. Pharmaceutical care, European developments in 
concepts, implementation, teaching, and research: a review. Pharm World Sci. 
2004;26(6):303-11. 
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account the amount of money needed to improve one QALY or any other 
effectiveness unit, the investment needed was low. The interesting point is 
that in four economic evaluations, PPSs turned out to be more effective and 
less costly than the UC, which is the optimal outcome when assessing a 
healthcare technology. Furthermore, the results provided by two of these 
studies were highly reliable since they were high quality studies. One of the 
PPSs was an adherence service for patients with chronic obstructive 
pulmonary disease77 whereas the other one was the first EE performed on the 
MRF of the conSIGUE Program68.  
Initially a CUA was proposed when developing the economic 
evaluation of the conSIGUE Program. However, when negotiating with local 
and national Spanish decision makers we realized that this analysis was 
insufficient for them to consider a payment for the service. The cost per 
QALY concept was difficult to understand and they were interested in the 
cost-savings generated by the MRF. Thus, we calculated the cost-savings and 
transformed the cost per QALY to a more easily interpretable cost-benefit 
ratio. 
In the conSIGUE Program, the MRF saved €97 per patient during the 
6-month follow-up for the health system. It was estimated that even if health 
administration paid €22 per patient-month, MRF would save €273 per 
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patient-year. In order to transform the cost per QALY to a cost-benefit ratio, 
a monetary value ranging from €13,863 to €25,905 obtained through 
contingent valuation in nine European countries was allocated to the QALY. 
Recently, a cost-effectiveness threshold ranging from €20,000 and €25,000 
per QALY by estimating the relation between the health expenditure and 
health has been suggested for Spain137. If one used this threshold as the 
monetary value of QALY in the cost-benefit analysis, the results would be 
very similar with the lower limit slightly higher. 
The MRF showed a cost-benefit ratio between €3.3:1 and €6.2:1, which 
indicates that for every €1 invested in MRF, a benefit of €3.3 to €6.2 can be 
expected. This cost-benefit ratio was similar to the median values of cost-
benefit ratios found in different systematic reviews32. The “benefit” concept 
includes both the improvements in health outcomes by allocating a monetary 
value to these improvements and the cost-savings generated by the service. 
The reason for the service generating net savings was that the extra costs of 
the service (the investment of the pharmacy, time of the practice change 
facilitator and the time of the pharmacists) were compensated with savings in 
medication, ED visits and especially the decrease in hospital admission costs.  
                                                 
137 El Global. [Spain has a cost-effectiveness threshold: between 20.000 and 25.000 € per 
QALY]. Madrid, June 2016. Available from: http://www.elglobal.net/noticias-
medicamento/2016-06-17/politica-sanitaria/el-coste-efectividad-ya-tiene-umbral-en-espana-
entre-20-000-y-25-000-%E2%82%ACavac/pagina.aspx?idart=988203. [Accessed August 5, 
2016]. 
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Hospital admissions are the most costly resource analysed in this 
research project. When we firstly analysed the hospital costs to calculate the 
cost-benefit ratio by allocating a mean cost to patient-reported hospital 
admissions, we realised that it was not a reliable method. We needed a more 
accurate strategy, thus DRG were used. Through this strategy we confirmed 
patient-reported information with official sources; we had more specific cost 
estimation for each hospital admission and the clinical description of the 
hospitalisations. This information was used to assess whether hospitalisations 
were related to medicines and to include in the analysis only those admissions 
related to medicines, lessening the variability in both clinical and economic 
analyses.  
The reporting of this process plus the necessity of generating evidence 
on the effectiveness of PPSs on health outcomes led to the third chapter of 
the thesis. This study evidenced the high prevalence of medication-related 
hospital admissions in elderly population using polypharmacy and the 
significant impact of the MRF on avoiding medication-related hospital 
admissions. Additionally, it showed that the MRF decreases hospital costs to 
the health system by means of reducing the number of hospitalisations. 
Our findings contrast with other studies in which the impact of PPSs 
on hospital admissions is uncertain. This uncertainty could be due to the 
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assessment of a different type of PPSs; different characteristics, rates of 
fidelity and implementation of the service; different patients´ baseline 
characteristics or not evaluating the association of hospital admissions with 
medicines. We found a significant impact of the MRF on the number and 
costs of medication-related hospital admissions in the polymedicated elderly, 
although confidence intervals were wide. The variability could be due to the 
small number of hospitalisations, a common limitation in studies analysing 
hospitalised patients after receiving a pharmacist-led intervention133,134. 
Hospital admissions are infrequent events and at the same time, the impact 
on patients´ health outcomes and healthcare resources is high. Thus, hospital 
admissions must be recorded accurately. In future studies a system that goes 
beyond patients´ self-reporting and that standardises public and private health 
systems´ registries is needed to ensure the correct recording of all the hospital 
admissions.  
The final aim of EE is to provide policy makers with information to 
facilitate the process of decision making in rational choice among alternative 
technologies. Therefore the generation of accurate, reliable and easily 
understandable results is needed. The method used to report the results was 
specifically one of the objectives in two of the three papers released in the 
context of the present thesis, since in the beginning of the process we realised 
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that the most frequent tools used to report the results of the EE were not the 
most appropriate to communicate with decision makers. It seems important 
to diminish the gap between non-health economist decision makers and the 
complex concepts, methodology and interpretation of health economic 
results, in order to foster the process of accepting new technologies that will 
promote the efficiency of the health system. 
Health innovation relies on demonstrating that the technology is safe, 
effective, cost-effective, affordable and how will the technology be adopted 
and disseminated in the practice138. Overall, PPSs provided in community 
pharmacy have demonstrated to be effective and cost-effective (see chapter 
1). Particularly the MRF is a dominant strategy for the Spanish health system. 
Since the MRF improves health outcomes while saving money to the health 
system, decision makers should consider including the MRF in the primary 
care service portfolio.  
However the affordability of MRF for the NHS should be analysed as 
well, considering what the likely population to receive the service is and what 
the overall costs would be. To address this issue, a budget impact analysis 
should be undertaken. This budget impact analysis would most likely be 
                                                 
138 National Information Center on Health Services Research and Health Care Technology 
(NICHSR). Chapter II: Fundamental concepts. U.S. National Library of Medicine. Available 
from: https://www.nlm.nih.gov/nichsr/hta101/ta10104.html. [Accessed July 27, 2016]. 
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positive since the MRF is less costly than the UC. The health system should 
generate a new budget line for the payment of the service, taking into account 
not the incremental differences between the MRF and the UC but the total 
costs, savings and budget constraints. Finally, the adoption and dissemination 
of the technology in the practice should be discussed, taking into account the 
funding, availability and equity of access to the service. Once implemented, 
the adoption and the use of the service in routine delivery should be 
monitored138. 
Health promotion strategies provided in primary care are one of the 
strategies suggested to promote the sustainability of health systems in some 
core reports released by the World Health Organization4,6. The MRF service 
is an intervention provided in primary care setting, targeted at polymedicated 
elderly and focused on the prevention and solution of DRPs and NCOMs 
and improving the control of chronic diseases. One of the key ideas suggested 
in these reports is that “by expanding the scope of what primary care settings 
can provide, if more (healthcare) can be provided within primary care, less 
needs to be provided in more resource intensive settings”6. Spanish 
community pharmacists currently provide basic services such as dispensing 
and minor ailments advice47. Providing services with the complexity and 
responsibility level required by the MRF would suppose an expansion of the 
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role of the pharmacists. Additionally, these reports released by the WHO 
state that given the long-term implications, the strategies to meet the needs of 
ageing populations must be introduced in health systems even in the current 
economic crisis4. Therefore the current investment in the implementation of 
the MRF would be justified since the later these interventions are 
implemented, the higher will be the financial impact of using secondary care 
resource-intensive settings. 
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1. The systematic review of economic evaluations based on randomized 
controlled trials concluded that professional pharmacy services, i.e. 
those activities in which the pharmacists would use their professional 
knowledge and abilities to improve pharmacotherapy and disease 
management by means of interacting with the patient or with other 
health professional, are overall cost-effective compared with the usual 
care provided in the community pharmacy. Four studies concluded 
that professional pharmacy services were dominant, since they 
improved patients’ clinical outcomes and health-related quality of life 
while saved costs to the healthcare system. The majority of the studies 
concluded that professional pharmacy services could improve 
patients’ outcomes with a financial investment far below the cost-
effectiveness threshold. 
 
2. The existing evidence on the cost-effectiveness of professional 
pharmacy services provided in community pharmacy should be 
complemented with more high quality studies assessing each 
individual service, due to the low number of studies published, limited 
comparability and the uncertainty related to some incremental cost-
effectiveness ratios. Those professional pharmacy services that have 
already been assessed through high quality studies and obtained 
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positive and robust cost-effectiveness results, could be considered by 
policy makers to be implemented within specific health systems of 
different countries.  
 
3. Medication review with follow-up, a professional pharmacy service 
aimed at resolving both drug related problems and their negative 
clinical outcomes through an optimisation of the medication, 
provided by community pharmacists and targeted to aged 
polypharmacy patients, was the dominant alternative in the 
conSIGUE Program, since it avoided €97 per patient in 6 months to 
the health system besides providing health benefits to patients. 
Investment in the implementation of this service would represent an 
efficient use of healthcare resources since for every €1 invested, a 
benefit of €3.3 to €6.2 can be expected. 
 
4. In the conSIGUE Program, 50% of the hospital admissions in elderly 
patients using polypharmacy were associated with the ineffective and 
unsafe use of medicines. Medication review with follow-up provided 
by community pharmacists has a positive impact on medication-
related hospital admissions, since the probability of being hospitalised 
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was 3.7 times higher in the comparison group compared with the 
intervention group. 
 
5. The impact of the medication review with follow-up service provided 
by community pharmacists on medication-related hospital admissions 
led to a decrease in hospital costs. The mean hospital cost per elderly 
patient using polypharmacy in the intervention group of the 
conSIGUE Program was three times lower than for patients in the 
comparison group. 
 
6. Community pharmacist-led medication review with follow-up is a 
cost-effective strategy to meet ageing population´s health needs, 
decrease the preventable clinical and economic burden caused by drug 
related problems and in long-term, promote the sustainability of the 
Spanish health system. 
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Conclusiones 
1. La revisión sistemática de evaluaciones económicas basadas en 
ensayos controlados aleatorizados permite concluir que los servicios 
profesionales farmacéuticos, entendidos como las actividades en las 
que el farmacéutico utiliza su conocimiento y habilidades 
profesionales para mejorar la farmacoterapia y el manejo de las 
enfermedades interactuando con el propio paciente o con otros 
profesionales sanitarios son, en general, coste-efectivos en 
comparación con la atención habitual realizada en la farmacia 
comunitaria. Cuatro estudios concluyeron que los servicios 
profesionales farmacéuticos evaluados eran dominantes, ya que 
mejoraban los resultados en salud de los pacientes a la vez que 
generaban un ahorro para el sistema sanitario. La mayoría de los 
estudios concluyeron que los servicios profesionales farmacéuticos 
pueden mejorar los resultados en salud de los pacientes con una 
inversión económica muy por debajo del umbral de coste-efectividad. 
 
2. La evidencia disponible sobre el coste-efectividad de los servicios 
profesionales farmacéuticos realizados en farmacia comunitaria 
debería ser complementada con estudios adicionales de calidad que 
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evalúen individualmente cada servicio, debido al bajo número de 
estudios publicados, limitada comparabilidad  y la incertidumbre 
relacionada con algunos de los ratios de coste-efectividad incremental. 
En el caso de los servicios que ya han sido evaluados mediante 
estudios de calidad y han obtenido resultados de coste-efectividad 
positivos y robustos, son susceptibles de ser valorados por los 
decisores sanitarios para ser implantados en los sistemas sanitarios 
específicos de diferentes países. 
 
3. El seguimiento farmacoterapéutico, servicio profesional farmacéutico 
dirigido a resolver tanto los problemas relacionados con la medicación 
como los resultados clínicos negativos de los mismos a través de la 
optimización de la medicación, realizado por farmacéuticos 
comunitarios y dirigido a pacientes mayores polimedicados, demostró 
en el Programa conSIGUE ser la alternativa dominante en 
comparación con la atención habitual, ya que ahorró 97€ al sistema 
sanitario por paciente en 6 meses, además de proporcionar beneficios 
en salud a los pacientes. La inversión en la implantación de este 
servicio representaría un uso eficiente de los recursos sanitarios, ya 
que por cada 1€ invertido, el servicio proporcionaría un beneficio de 
entre 3,3€ y 6,2€. 
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4. La mitad de los ingresos hospitalarios sufridos por los pacientes 
mayores polimedicados participantes en el Programa conSIGUE 
estaban asociados al uso inefectivo e inseguro de los medicamentos. 
El seguimiento farmacoterapéutico realizado por farmacéuticos 
comunitarios ejerció un impacto positivo en el número de ingresos 
hospitalarios relacionados con la medicación, en tanto que la 
probabilidad de ser ingresado fue 3,7 veces mayor en el grupo 
comparación respecto al grupo intervención. 
 
5. El impacto del servicio de seguimiento farmacoterapéutico realizado 
por farmacéuticos comunitarios en los ingresos hospitalarios 
relacionados con la medicación se tradujo en una disminución de los 
costes hospitalarios, siendo el valor medio de este coste por cada 
paciente mayor polimedicado en el grupo intervención del Programa 
conSIGUE tres veces menor que en los pacientes del grupo 
comparación.  
 
6. El seguimiento farmacoterapéutico realizado por farmacéuticos 
comunitarios resulta ser una estrategia coste-efectiva para responder a 
las necesidades sanitarias de la población mayor, reducir la carga 
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clínica y económica prevenible causada por los problemas 
relacionados con los medicamentos y a largo plazo, promover la 
sostenibilidad del sistema sanitario en España. 
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